

# Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3



Global Burden of Disease Health Financing Collaborator Network\*

## Summary

**Background** Sustainable Development Goal (SDG) 3 aims to “ensure healthy lives and promote well-being for all at all ages”. While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available.

**Methods** We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For disease-specific health spending, we estimated spending for HIV/AIDS and tuberculosis for 135 low-income and middle-income countries, and malaria in 106 malaria-endemic countries, from 2000 to 2017. We also estimated development assistance for health (DAH) from 1990 to 2019, by source, disbursing development agency, recipient, and health focus area, including DAH for pandemic preparedness. Finally, we estimated future health spending for 195 countries and territories from 2018 until 2030. We report all spending estimates in inflation-adjusted 2019 US\$, unless otherwise stated.

**Findings** Since the development and implementation of the SDGs in 2015, global health spending has increased, reaching \$7.9 trillion (95% uncertainty interval 7.8–8.0) in 2017 and is expected to increase to \$11.0 trillion (10.7–11.2) by 2030. In 2017, in low-income and middle-income countries spending on HIV/AIDS was \$20.2 billion (17.0–25.0) and on tuberculosis it was \$10.9 billion (10.3–11.8), and in malaria-endemic countries spending on malaria was \$5.1 billion (4.9–5.4). Development assistance for health was \$40.6 billion in 2019 and HIV/AIDS has been the health focus area to receive the highest contribution since 2004. In 2019, \$374 million of DAH was provided for pandemic preparedness, less than 1% of DAH. Although spending has increased across HIV/AIDS, tuberculosis, and malaria since 2015, spending has not increased in all countries, and outcomes in terms of prevalence, incidence, and per-capita spending have been mixed. The proportion of health spending from pooled sources is expected to increase from 81.6% (81.6–81.7) in 2015 to 83.1% (82.8–83.3) in 2030.

**Interpretation** Health spending on SDG3 priority areas has increased, but not in all countries, and progress towards meeting the SDG3 targets has been mixed and has varied by country and by target. The evidence on the scale-up of spending and improvements in health outcomes suggest a nuanced relationship, such that increases in spending do not always results in improvements in outcomes. Although countries will probably need more resources to achieve SDG3, other constraints in the broader health system such as inefficient allocation of resources across interventions and populations, weak governance systems, human resource shortages, and drug shortages, will also need to be addressed.

**Funding** The Bill & Melinda Gates Foundation.

**Copyright** © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

## Introduction

In 2015, the 193 member states of the United Nations (UN) adopted the 2030 Agenda for Sustainable Development. The agenda identified 17 Sustainable Development Goals (SDGs) and 169 targets intended to catalyse “peace and prosperity for people and the planet”. Of the 17 goals, many address health indirectly (eg, zero hunger [SDG2], gender equality [SDG5], and clean water and sanitation [SDG6]), while SDG3 focuses directly on health, with the objective being to “ensure healthy lives and promote well-being for all at all ages.”

Substantial effort has been made to quantify the progress towards meeting the targets set in SDG3.<sup>1,2</sup> Examples include WHO’s Thirteenth General Programme of Work, which provides a framework for tracking progress towards the health-related SDGs and research done by the Global Burden of Diseases, Injuries, and Risk Factors study (GBD) Collaborator Network, while less research has focused on tracking spending on SDG priority areas, especially how they relate to specific SDG3 indicators.<sup>3</sup> Tracking financial resources for SDG3 priority areas is crucial for two distinct reasons. First, any

Published Online  
April 23, 2020  
[https://doi.org/10.1016/S0140-6736\(20\)30608-5](https://doi.org/10.1016/S0140-6736(20)30608-5)  
See Online/Comment  
[https://doi.org/10.1016/S0140-6736\(20\)30963-6](https://doi.org/10.1016/S0140-6736(20)30963-6)

\*Listed at the end of the Article

Correspondence to:  
Dr Joseph L Dieleman, Institute for Health Metrics and Evaluation, Seattle, WA 98121, USA  
[dieleman@uw.edu](mailto:dieleman@uw.edu)

For Sustainable Development Goals Knowledge Platform see <https://sustainabledevelopment.un.org/sdgs>

For WHO’s Thirteenth General Programme of Work see <https://apps.who.int/iris/bitstream/handle/10665/324775/WHO-PRP-18.1-eng.pdf>

### Research in context

#### Evidence before this study

The Sustainable Development Goals (SDGs) and their related indicators and targets mark a consensus among global leaders about the importance of improving and maintaining health worldwide. To monitor progress towards the health-related SDGs, the United Nation's Voluntary National Reviews Database, WHO, and the Global Burden of Diseases, Injuries, and Risk Factors study (GBD) Collaborator Network have measured health indicators to monitor achievement of SDG3, and the World Bank created the SDG atlas. A multitude of voices are championing progress towards achieving the SDGs, with some also proposing estimates of the financing needs to meet the related health goals. To track financing inputs for health, previous studies by the GBD Health Financing Collaborator Network have estimated past and projected future total health spending in 195 countries and territories from 1995 to 2050, and health investment from international donors to low-income and middle-income countries between 1990 and 2050. In the most recent study, in which spending was estimated in 2018 US\$, global health spending was found to reach \$8.0 trillion (95% uncertainty interval 7.8–8.1) comprising 8.6% (8.4–8.7) of the global economy in 2016 and was projected to increase to \$15.0 trillion (14.0–16.0), that is 9.4% (7.6–11.3), of the global economy by 2050. Additionally, estimates have been published for HIV/AIDS spending in low-income and middle-income countries and malaria spending in 106 malaria-endemic countries (also from the GBD Collaborator Network). Similarly, UNAIDS and WHO have estimated for spending on HIV/AIDS, tuberculosis, and malaria in many low-income and middle-income countries. The studies from the GBD Health Financing Collaborator Network showed that in 2016, US\$19.9 billion (15.8–26.3) was spent on HIV/AIDS and \$4.3 billion (4.2–4.4) was spent on malaria. The World Malaria Report published by WHO in 2019 showed that US\$2.7 billion was invested in malaria control and elimination activities by international partners and governments of malaria endemic countries. For HIV/AIDS, UNAIDS Global AIDS monitoring report showed that in 2018, \$19 billion (in 2016 US\$) from international and domestic sources was spent and the WHO's Global Report on tuberculosis reported that in 2019 \$6.8 billion was spent on tuberculosis diagnosis, prevention, and treatment services. Additionally, the Sustainable Development Solutions Network, the International Monetary Fund, World Bank, and Organization for Economic Co-operation and Development have offered different methods, assumptions, and measures related to the financing needs for SDG3. The Working Group on SDG Costing and Financing has worked to mobilise costing practices and tools to achieve the SDGs.

For SDG3 specifically, the Third Edition of the Disease Control Priorities in Developing Countries assessed financial needs for universal health coverage, while researchers at the Institute of Health Metrics and Evaluation have estimated funding gaps to achieve universal health coverage. The Department of Health Systems Governance and Financing at WHO has also projected resource needs to finance transformative health systems towards achievement of SDG3. Beyond estimated financing targets, needs, and gaps, only four of 27 SDG3 indicators have estimates of past or current total spending. These financial estimates are not directly comparable due to differences in study designs, scopes, and completeness.

#### Added value of this study

This study is the first to our knowledge, that assesses spending on and explores the association with health gains for key SDG3 targets related to HIV/AIDS (3.3.1), tuberculosis (3.3.2), malaria (3.3.3), universal health coverage (3.8.1), financial risk protection (3.8.2), and development assistance for health (DAH; 3.b.2). We focused on quantifying total health spending on HIV/AIDS, malaria, and tuberculosis and DAH contributions. Additionally, we provide updated estimates using consistent methods for retrospective and prospective total health sector spending. This work adds value to existing literature by using similar methods as previous studies to quantify progress in financing SDG3 priority by estimating domestic spending by source spending on four SDG3 indicators and DAH funding on eight SDG3 indicators.

#### Implications of all available evidence

Tracking progress towards the financing of health systems and specific targets associated with SDG3 draws attention to the need for sufficient resources to achieve health gains without placing financial hardship on households. Monitoring this progress requires comparable and consistent estimates in financing for health. By providing these estimates, we create a foundation for stakeholders to discuss, set, and reach achievable financial goals. In particular, for some low-income countries our results highlight that the available resources seem insufficient to achieve the SDG3 targets by 2030. This study also highlights the need to estimate the financing available for the other SDG3 priority areas. Furthermore, the nuanced evidence on the scale-up of spending and improvements in health outcomes suggest a complex association between spending and health outcomes. This complexity highlights that, although more resources are probably needed to achieve SDG3, other constraints such as inefficient resource allocation, weak governance systems, inadequate health workforce, and drug shortages will likely need to be addressed to achieve the SDG3 targets.

scale-up of the interventions needed to achieve the ambitious health goals will probably require some additional resources. As such, tracking how many resources are spent on health, when and where those resources are spent, and who benefits from them is vital for transparency and assessment of progress towards the goals.<sup>4</sup>

Furthermore, the amount of financial investment in health and how it is spent might be used as a proxy for governments' commitment to achieving SDG3 and health services more broadly. Even in instances where more resources are not needed to achieve the goals (because gains can be made through improvements in

efficiency of health systems), knowing precisely how much is being spent and for what purpose is essential for tracking effectiveness and ensuring an equitable distribution of resources. Second, SDG3 target 3.8 identifies financial risk protection and access to essential services as key targets.<sup>5</sup> Financial risk protection is ensuring that no household endures financial hardship due to large spending on health. Achieving SDG3 target 3.8 not only requires enough resources are available to provide the services and interventions needed to prevent and treat ill health, but also that an awareness of the source of those funds is key. Ensuring that health spending does not lead to financial hardship and impoverishment, known as catastrophic health spending, requires that funds for health be prepaid and pooled across individuals via public or private insurance schemes.<sup>6</sup> The alternative to prepaid and pooled resources for health is reliance on out-of-pocket spending, which forces households without sufficient resources to choose between receiving health care or medical impoverishment.

This study builds on past work and aims to make progress towards filling the current gap in knowledge on the financing of SDG3 priority areas.<sup>7–9</sup> Little evidence exists on how much is being spent towards the SDG3 targets and how this spending relates to changes in health outcomes of interest. The objectives of this study are to measure spending on SDG3 priority areas where estimates are relatively complete and comparable, examine the association between outcomes and financing levels, and identify where resource shortages are most apparent for four SDG3 indicators. We quantified health spending for universal health coverage; domestic and DAH spending on HIV/AIDS, tuberculosis, malaria; and DAH spending for reproductive, maternal, newborn, and child health, tobacco control, non-communicable diseases, vaccines, and human resources. We also evaluated spending against key SDG3 indicators for HIV/AIDS, tuberculosis, malaria, universal health coverage, and pandemic preparedness. Additionally, this research estimates future spending on health up to 2030 and 2050 to highlight the expected resource availability and, in particular, provides information that can be used to identify where more prepaid and pooled resources are needed.

## Methods

### Overview

We measured health sector spending by source; domestic spending on HIV/AIDS, tuberculosis, and malaria; and development assistance for health (DAH; ie, from donors) for as many years as possible with the availability of input data. For total health sector spending and domestic health spending, we generated estimates for 1995–2017 for 195 countries and territories; for domestic spending on HIV, tuberculosis, and malaria, we generated estimates for 2000–17 for 135 low-income and middle-income countries (although for malaria, 28 low-income and

middle-income countries without endemic malaria were excluded); and for DAH, we generated estimates for 1990–2019 and all low-income and middle-income countries. Using these health spending estimates, we projected health sector spending to 2030 and 2050. We define health spending similarly to the System of Health Accounts 2011 and the WHO Global Health Expenditure Database as spending on basic infrastructure, services, and supplies to deliver health care. This health spending is exclusive of informal care spending and major capital investments, such as building hospitals.

### Domestic health spending 1995–2017

We estimated three sources of domestic health spending: government, out-of-pocket, and prepaid private spending.<sup>7</sup> The sum of spending from these three domestic sources, plus DAH, equate to total spending on health, meaning these four sources are mutually exclusive and collectively exhaustive. Government health spending is an aggregate of social health insurance and government public health programmes. Out-of-pocket health spending captures health-care spending by an individual patient or their household, excluding insurance premiums paid before needing care. Prepaid private-health spending includes non-governmental agency spending on health and private insurance. To estimate the three domestic health spending variables, we extracted data from the WHO Global Health Expenditure database for all available countries.<sup>10</sup> We downloaded the data in current national currency units, adjusted for inflation, and then converted to 2019 \$US, completed our analysis, and then also converted our estimates into 2019 purchasing-power parity-adjusted \$. We used deflator series and exchange rate data based on data from the International Monetary Fund World Economic Outlook.<sup>11</sup> For each extracted datapoint, we used the metadata provided by WHO to qualitatively assess the quality of data. We assigned a weight to each downloaded datapoint on the basis of documented source information, completeness of metadata, and documented methods of estimation (more details are in the appendix [pp 14–21]). We then used a spatiotemporal Gaussian process model to generate a complete time series of data from 1995 until 2017 for each country, and 95% uncertainty intervals (UIs).<sup>12</sup>

### Domestic spending on HIV/AIDS, tuberculosis, and malaria 2000–17

We generated estimates of domestic spending for three communicable diseases included in the SDG target 3.3: HIV/AIDS, tuberculosis, and malaria. To generate the three disease-specific spending estimates, we used a similar overarching strategy as for domestic health spending estimates. First, we did a comprehensive search and extracted all available and applicable data, which we put into a common currency for comparability (2019 US\$). The input data for our disease-specific spending estimates came from multiple sources.

For **System of Health Accounts** see <https://www.who.int/health-accounts/methodology/en/>

For **WHO Global Health Expenditure Database** see <https://apps.who.int/nha/database>

See [Online](#) for appendix

For the **Global Fund website** see <http://www.theglobalfund.org/en>

For **AIDSinfo database** see <https://aidsinfo.unaids.org/>

For **UNAIDS HIV financial dashboard** see <http://hivfinancial.unaids.org/hivfinancialdashboards.html>

For **Asia-Pacific region HIV Data Hub** see <http://aphub.unaids.org/>

For **WHO tuberculosis database** see <http://www.who.int/tb/data/en/>

For **WHO-CHOICE website** see <https://www.who.int/choice/cost-effectiveness/en/>

For the **World Malaria Report** see <https://www.who.int/malaria/publications/world-malaria-report-2018/en/>

For HIV/AIDS, we extracted spending data for 135 low-income and middle-income countries from the National AIDS Spending Assessments,<sup>13</sup> the Global Fund (including concept notes, proposals, and funding landscape documents), National Health Accounts and subaccounts, UNAIDS Global AIDS response progress reports, and three online public databases provided by UNAIDS: the AIDSinfo database, the HIV financing dashboard, and the Asia-Pacific region AIDS Data Hub. Additional details on the data sources we used are in the appendix (pp 113–16).

For tuberculosis, we extracted spending data for 135 low-income and middle-income countries from the WHO Global Tuberculosis database, Global Fund (proposals, concept notes, and funding landscaping documents), National Health Accounts and sub-accounts, WHO Global Health Expenditure database,<sup>10</sup> National Tuberculosis Reports, Ministry of Health Reports, GBD data, and unit cost data from WHO-Choosing Interventions that are Cost Effective (CHOICE), and Moses et al.<sup>14</sup> Additional details on the data sources we used are in the appendix (pp 13–21).

For malaria, we extracted spending data for 106 malaria-endemic low-income and middle-income countries from the World Malaria Report, the Global Fund (including concept notes, proposals, and funding landscape documents), National Health Accounts and sub-accounts, the Global Fund Price Quality Reporting, WHO Global Price Reporting Mechanism, Management Sciences for Health reference prices, Global Affordable Medicine Facility, Health Action International database, treatment data provided by the Malaria Atlas Project, Demographic and Health Surveys, malaria out-of-pocket cost literature, malaria inpatient and outpatient cost literature, and inpatient and outpatient unit costs from Moses et al.<sup>14</sup> Further details on the data sources we used are in the appendix (pp 89–90).

Second, we used a spatiotemporal Gaussian process model to generate a complete time series of estimates by disease from 2000 to 2017 for each country included. For our HIV/AIDS spending estimates, tabulated data of annual spending of all components—government, out-of-pocket, and prepaid private spending—were available, so we used those to generate our estimates. For malaria and tuberculosis, little tabulated data and estimates on out-of-pocket spending were available, so we developed out-of-pocket spending estimates by taking the product of coverage (ie, volume) and unit costs for key services for which users pay out of pocket.

#### Universal health coverage, 2000–17

We extracted the universal health coverage service index from the GBD 2017 SDG Collaborators.<sup>1</sup> The index aggregates across a diverse set of intermediate coverage estimates, such as vaccine coverage, and measured of health system performance. We extracted data on 195 countries from 2000 to 2017 used these data in this analysis.

No commonly agreed on system exists to differentiate between which health spending is intended to help countries achieve universal health coverage. Because of this, we track pooled health spending as a proxy for tracking progress towards financing universal health service coverage. Pooled spending is health-care spending collected in advance and spread across a large set of individuals, and includes government and prepaid private spending and DAH.

#### Estimating DAH, 1990–2019

We defined DAH as the financial and in-kind resources transferred through international development agencies to low-income and middle-income countries for the primary purpose of maintaining and improving health. We extracted project disbursement data from online databases, annual reports, and financial statements of the major international development agencies and philanthropic institutions including the World Bank, the Organisation for Economic Co-operation and Development's (OECD's) Creditor Reporting System, and the Bill & Melinda Gates Foundation; details on the agencies and institutions included are in the appendix (pp 28–33). The estimates of DAH include the expenses incurred to administer the grants and loans.

We classified estimates of how DAH funds were disbursed into ten mutually exclusive and collectively exhaustive health focus areas and 52 programme areas on the basis of project descriptions, project titles, including pandemic preparedness, and budget documents. Disbursement of DAH funds to single countries were identified as such, while global initiatives and administrative costs were classified separately. Administrative costs capture the operational cost of running projects—eg, staff salaries. The research and development funds that are included in our DAH estimates are those that are disbursed through international development agencies with the primary intent of the improvement and maintenance of health in low-income and middle-income countries. The DAH contributions towards human resources we captured here include indirect funding for human resources activities, such as per diems, and direct funding for human resources for health projects that invest in human resources activities, such as training, education, and policy development. The health focus areas included in this study are HIV/AIDS; tuberculosis; malaria; reproductive, maternal, newborn, and child health; other infectious disease; non-communicable diseases; sector-wide approaches; and health system strengthening. Detailed descriptions of the methods we used to isolate the disbursements of DAH funds for relevant health focus areas and preliminary estimates are in the appendix (pp 34–45) and elsewhere.<sup>7,15</sup>

The estimates presented here of DAH incorporated improvements in our methods compared with previous years, such as using additional project-level descriptions

from the Creditor Reporting System for the allocation of disbursements channelled through non-governmental organisations and refinement of our keyword search list (appendix 34–42).

The Millennium Development Goals (MDGs) were eight development goals adopted by the UN in 2000. The goals, to be achieved by 2015, included the eradication of extreme poverty and hunger; achievement of universal primary enrolment; promotion of gender equality and empowerment of women; reduction in child mortality, HIV/AIDS, malaria, and other diseases; and improvement in maternal health. Like the SDGs, the MDGs included health specific goals and goals focused on other sectors indirectly linked to health. In our analyses, we examine spending over the duration of the MDGs, starting in 2000 up to 2015.

DAH data for 2018 and 2019 are preliminary estimates based on budget data and estimation. Detailed information on the sources of the budget data and the estimation approaches we used are provided in the appendix (pp 29–33).

### Financial risk protection

We extracted incidence data on catastrophic health spending estimates from World Bank World Development Indicators database for all years and countries for which data were available. Reliance on out-of-pocket spending has been shown to be associated with catastrophic health spending (also known as medical impoverishment),<sup>16,17</sup> which defined by the World Bank World Development index as when a household spends more than 25% of annual household income on health.

### Health spending in the future: 2018 to 2030 and 2050

We estimated gross domestic product (GDP); general government spending (across all sectors); government, out-of-pocket, and prepaid private health spending; and total DAH provided and received from 2018 to 2030 and 2050. The methods used for these projections draw heavily from our previous research,<sup>7,18,19</sup> with the key updates being the improvement of the retrospective estimates on which these projections are based.

We generated each projection using ensemble modelling techniques, such that the estimates are the mean of 1000 estimated time series from a broad set of models. We determined model selection on the basis of out-of-sample validation and selection was country and year specific. We completed projections sequentially, such that previously projected values could be used as covariates and for bounding other models. For example, government health spending was modelled as a fraction of general government spending, which was modelled as a fraction of GDP. On the basis of model performance, we modelled GDP as a proportion of the population who were of working age, which for this study was determined to be aged 20–65 years.

We modelled DAH as a fraction of the donor country's general government spending, or, for private donors, on

the basis of autoregressive integrated moving average (ARIMA) modelling techniques.<sup>20</sup> We aggregated total DAH across sources. We constructed a separate model that projected the fraction of total DAH that each recipient was expected to receive. As a country's own GDP per-capita increases, the fraction of total DAH received by the country is expected to go down. We also modelled when countries transitioned to being high-income and are no longer eligible to receive DAH.

All projections incorporated several types of uncertainty. We used ensemble modelling techniques to propagate model uncertainty.<sup>21</sup> We took draws of the variance-covariance matrix of each estimate's model to propagate parameter uncertainty. We based our projection models on the draws of the retrospective estimates to propagate data uncertainty. Finally, we added a random walk residual to each country's and draw's projection to propagate fundamental uncertainty—ie, to mimic the inherent randomness of the observed data. We generated 95% uncertainty intervals (UIs) by taking the 2.5th and 97.5th percentile of the 1000 estimated random draws.

More details are in the appendix (pp 121–41).

### Statistical analysis

We report all spending estimates in inflation-adjusted 2019 US\$, although some data are also presented in 2019 purchasing-power parity-adjusted \$ and proportion of GDP. We report spending estimates for Venezuela in 2014 US\$ because necessary exchange rates for more recent years were not reliable. We evaluated health spending against key indicators relative to SDG3. In particular, we extracted estimates of incidence of HIV/AIDS, tuberculosis, and malaria from GBD 2017,<sup>22</sup> and the universal health coverage service coverage index.<sup>1,23</sup>

We used different measures to report findings from our spending and outcomes analyses. For HIV/AIDS, we report spending per prevalent case, because a lot of HIV/AIDS spending is determined by the number of people undergoing treatment. For malaria, we report spending per capita, because as countries move towards elimination a lot of malaria spending is on surveillance. For tuberculosis, we report spending per incident case, because a lot of tuberculosis spending is determined by detection of incident cases. Population estimates, both retrospective and prospective were also extracted from the GBD 2017 study.<sup>24</sup> We analysed the association between universal health coverage service index and pooled health spending by calculating the annualised rate of change in each metric from 2000 up to 2017. For our financial risk protection analysis, we used the estimates of catastrophic health spending and report catastrophic health spending estimates from the World Bank World Development Indicators database. We divided the extracted estimates by total domestic spending on health and then regressed on national income using loess regression methods. Annualised rate of change is only calculated for countries

For more on the **Millennium Development Goals** see [https://www.undp.org/content/undp/en/home/sdgoverview/mdg\\_goals.html](https://www.undp.org/content/undp/en/home/sdgoverview/mdg_goals.html)



with more than 1 year of catastrophic health spending estimates and when catastrophic health spending was greater than zero.<sup>25,26</sup> We report estimates of DAH from 1990 up to 2019 for low-income and middle-income

countries. The data for 2018 and 2019 are preliminary estimates based on budget data and estimation. We compared DAH contributions over two periods: 2000 up to 2015 and 2015 up to 2019. We also analysed DAH by

	SDG target	Spending estimate	Existing unofficial financing target
<b>Target 3.1: by 2030, reduce the global maternal mortality ratio &lt;70 per 100 000 livebirths</b>			
3.1.1: maternal mortality ratio	Reduce to <70 deaths per 100 000 livebirths by 2030	DAH funding on maternal health was \$1.5 billion for 135 low-income and middle-income countries in 2019	\$10.5 billion per year in 120 low-income and middle-income countries (UNFPA Nairobi Summit ICPD25, <sup>27</sup> estimated \$115.5 in 2020–30); \$3.3 billion* (2014 US\$) per year in 67 low-income and middle-income countries <sup>28</sup>
3.1.2: skilled birth attendance	Universal access (100%)	..	..
<b>Target 3.2: by 2030, end preventable deaths of newborn babies and children younger than 5 years, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1000 livebirths and under-5 mortality to at least as low as 25 per 1000 livebirths</b>			
3.2.1: under-5 mortality	Reduce to ≤25 deaths per 1000 livebirths by 2030	DAH on child health was \$8.5 billion for 135 low-income and middle-income countries in 2019	..
3.2.2: neonatal mortality	Reduce to ≤12 deaths per 1000 livebirths by 2030	DAH on child health was \$8.5 billion for 135 low-income and middle-income countries in 2019	..
<b>Target 3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other communicable diseases</b>			
3.3.1: HIV incidence	Eliminate by 2030	Domestic spending in 2017 was \$10.6 billion and DAH was \$9.5 billion in 2019 for 135 low-income and middle-income countries	\$26.2 billion per year by 2020 and \$22.3 billion per year by 2030 in 116 low-income and middle-income countries; <sup>29</sup> \$6.8 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
3.3.2: tuberculosis incidence	Eliminate by 2030	Domestic spending was \$9.2 billion in 2017 and DAH was \$1.7 billion in 2019 for 135 low-income and middle-income countries	\$13 billion by 2022 in 119 low-income and middle-income countries; <sup>30</sup> \$3.8 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
3.3.3: malaria incidence	Eliminate by 2030	Domestic spending in 2017 was \$2.6 billion and DAH was \$1.1 billion in 2019 on malaria for 106 malaria-endemic countries	\$6.6 billion per year by 2020 <sup>31</sup>
3.3.4: hepatitis B incidence	Undefined	..	\$6 billion* per year in 67 low-income and middle-income countries <sup>28,32</sup>
3.3.5: neglected tropical diseases prevalence	Eliminate by 2030	..	\$2.1 billion per year in low-income and middle-income countries <sup>33</sup>
<b>Target 3.4: by 2030, reduce premature mortality from non-communicable diseases by a third through prevention and treatment and promotion of mental health and wellbeing</b>			
3.4.2: non-communicable disease mortality	Reduce by a third by 2030	DAH on non-communicable disease was \$0.7 billion for 135 low-income and middle-income countries in 2019	\$28 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
3.4.2: suicide mortality	Reduce by a third by 2030	..	..
<b>Target 3.5: strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol</b>			
3.5.1: substance abuse coverage	Undefined	..	\$2 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
3.5.2: alcohol use	Undefined	..	..
<b>Target 3.6: by 2020, halve the number of global deaths and injuries from road traffic accidents</b>			
3.6.1: road injury mortality	Reduce by half by 2020	..	..
<b>Target 3.7: by 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes</b>			
3.7.2: family planning need met, modern contraception methods	Universal access (100%)	DAH on family planning was \$1.2 billion for 135 low-income and middle-income countries in 2019	\$6.2 billion per year in 120 low-income and middle-income countries (UNFPA Nairobi Summit ICPD25, estimated \$68.5 billion for 2020–30) <sup>34</sup>
3.7.2: adolescent birth rate	Undefined	..	..

(Table 1 continues on next page)

	SDG target	Spending estimate	Existing unofficial financing target
(Continued from previous page)			
<b>Target 3.8: achieve universal health coverage, including financial risk protection, access to quality essential health-care services, and access to safe, effective, quality, and affordable essential medicines and vaccines for all</b>			
3.8.1: universal health coverage service coverage index	Universal access (100%)	Domestic spending in 2017 and donor funding in 2019 on health was \$7.9 trillion (95% UI 7.8–8.0) and \$40.6 billion for 195 countries	\$274–371 billion* per year in 67 low-income and middle-income countries; <sup>28</sup> \$575.57 billion† in 188 countries; <sup>14</sup> \$113–223 billion† in 83 low-income and lower-middle income countries; <sup>14,35</sup> \$76 per capita per year in 34 low-income countries and \$110 per capita per year in 49 lower-middle income countries; <sup>36</sup> \$110‡ per capita per year in 32 low-income developing countries; and \$175‡ per capita in 27 other low-income developing countries (required budget outlays) <sup>37</sup>
3.8.2: financial risk protection	<10% or <25% of total expenditure or income	..	..
<b>Target 3.9: by 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water, and soil pollution and contamination</b>			
3.9.1: air pollution mortality	Undefined	..	\$8.1 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
3.9.2: WaSH mortality,	Undefined	..	..
3.9.3: poisoning mortality	Undefined	..	..
<b>Target 3.a: strengthen the implementation of the WHO Framework Convention on Tobacco Control in all countries, as appropriate</b>			
3.a.1: smoking prevalence	Undefined	DAH on tobacco control was \$0.1 billion for 135 low-income and middle-income countries in 2019	
<b>Target 3.b: support the research and development of vaccines and medicines for communicable and non-communicable diseases that primarily affect developing countries; provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on TRIPS regarding flexibilities to protect public health, and, in particular, provide access to medicines for all</b>			
3.b.1: vaccine coverage	Coverage of all target populations (100%)	DAH on immunisation was \$3.1 billion for 135 low-income and middle-income countries in 2019	\$1.4 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
3.b.2: developmental assistance for research and health	Undefined	DAH on health was \$40.6 billion for 135 low-income and middle-income countries in 2019	..
3.b.3: essential medicines	Coverage of all target populations (100%)	DAH on immunisation was \$3.1 billion for low-income and middle-income countries in 2019	\$1.4 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
<b>Target 3.c: substantially increase health financing and the recruitment, development, training, and retention of the health workforce in developing countries, especially in the least developed countries and small island developing states</b>			
3.c.1: health worker density	Undefined	DAH on human resources was \$4.0 billion for 135 low-income and middle-income countries in 2019	\$8.1 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
<b>Target 3.d: strengthen the capacity of all countries, particularly developing countries, for early warning, risk reduction, and management of national and global health risks</b>			
3.d.1: international health regulation capacity	Undefined	DAH on human resources was \$4.0 billion for 135 low-income and middle-income countries in 2019	\$8.1 billion* per year in 67 low-income and middle-income countries <sup>28</sup>
Spending data are reported in inflation adjusted 2019 US\$, unless otherwise indicated. Data for HIV/AIDS and tuberculosis are reported for 135 low-income and middle-income countries, for malaria are for 106 malaria-endemic countries, for universal health coverage for 195 countries and territories, and for DAH for each SDG3 indicator for 135 low-income and middle-income countries except malaria. Existing unofficial financing targets have been extracted from literature review. Low-income and middle-income countries are grouped as defined by 2019 World Bank classification. SDG=Sustainable Development Goal. DAH=development assistance for health. UNFPA=United Nations Population Fund. ICPD25=25th International Conference on Development. WaSH=water, sanitation, and hygiene. TRIPS=Trade-Related Aspects of Intellectual Property Rights.*2014 US\$. †2017 US\$. ‡2018 US\$.			
<b>Table 1: Health-related goals, health indicators, health targets, and related spending for SDG3 targets</b>			

health focus area specifically reporting contributions towards reproductive, maternal, newborn and child health, tobacco control, vaccines, non-communicable diseases, and human resources. Finally, we report global,

income group, region, and country-specific estimates. Income groups are based on World Bank income group classification from 2019, while regions are GBD super-regions (central Europe, eastern Europe, and central Asia;

high-income; Latin America and Caribbean; north Africa and the Middle East; south Asia; southeast Asia, east Asia, and Oceania; and sub-Saharan Africa). Argentina is the only country in the World Bank category of low-income and middle-income countries to fall in the GBD high-income super-region; hence, in the present study we do not include Argentina, and its GBD super-region, in figures that disaggregate by GBD super-region. We report aggregate rates that reflect the group of countries or region as a whole, rather than a mean across the countries in that group or region.

We did all analyses using R (version 3.6.0) and Stata (version 15). All spending estimates used in this analysis are publicly available on the Global Health Data Exchange website.

### Role of the funding source

The funder of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study, and AEM and JLD had final responsibility for the decision to submit for publication.

### Results

Table 1 lists the SDG3 targets and the associated indicators for monitoring these targets, and reports existing estimates of financing needed for attaining these targets and our spending estimates. The targets and indicators were determined and agreed on by the member states of the UN, while the financing targets are unofficial estimates of resources needed produced by other researchers. Our estimates of disease-specific spending focus on domestic and DAH spending among 135 low-income and middle-income countries while spending on universal health coverage is measured for 195 countries and territories including high-income countries.

Globally, total health spending has increased since the start of the SDGs in 2015, reaching \$7.9 trillion (95% UI 7.8–8.0) in 2017, and is expected to increase to \$11.0 trillion (10.7–11.2) by 2030, and \$16.7 trillion (16.0–17.4) in 2050, although with substantial disparity across countries. In 2017, in low-income and middle-income countries, \$20.2 billion (17.0–25.0) was spent on HIV/AIDS, \$10.9 billion (10.3–11.8) was spent on tuberculosis, and in 106 malaria-endemic countries, \$5.1 billion (4.9–5.4) was spent on malaria. DAH was estimated to be \$40.6 billion in 2019, the most recent year for which data are available. Estimates of DAH in 2019 were also available for the following SDG3 health areas: maternal health (\$1.5 billion), neonatal and child health (\$8.5 billion), HIV/AIDS (\$9.5 billion), tuberculosis (\$1.7 billion), malaria (\$2.3 billion), non-communicable diseases (\$735.0 million), family planning (\$1.2 billion), tobacco control (\$66.2 million), vaccine (\$3.1 billion), and human resources (\$4.0 billion). Spending for several SDG3 indicators, including

hepatitis B incidence (3.3.4), substance abuse (3.5.1–5.2), road injuries (3.6.1), adolescent birth rate (3.7.2), and chemical and environmental pollution (3.9.1–9.3) do not have a large, comparable set of spending estimates for either development assistance or domestic spending and so are not included in these analyses.

In 2019, DAH for pandemic preparedness was estimated to be \$374 million (<1% of total DAH). \$2.4 billion (6%) of all DAH was for infectious diseases (other than HIV/AIDS, tuberculosis, and malaria) in 2019, but these funds were generally spent on treatment or disease focused efforts rather than pandemic preparedness more broadly. Despite DAH for pandemic preparedness being such a small fraction of total DAH, DAH for pandemic preparedness has grown faster than total DAH over the past 10 years. Since 2010, DAH for pandemic preparedness has more than doubled (increasing 8.1% annually from \$185.8 million in 2010), while total DAH has increased by only 1.9% annually. The development agency that provided the most DAH for pandemic preparedness in 2019 was the WHO.

In 2017, global health spending per capita was \$1048 (95% UI 1034–1062). Of this amount, 81.3% (80.7–81.8) was financed by domestic government and prepaid private health spending (table 2). Most health spending was in high-income countries, where health spending was \$5307 (5262–5351) per capita in 2017, of which 86.0% (85.7–86.2) was government and prepaid private health spending. In 2017, spending in upper-middle-income countries was \$487 (457–520) per capita and in lower-middle-income countries was \$84 (76–93) per capita. Of \$37 (36–39) spent per capita in low-income countries in 2017, 30.9% (28.5–33.6) was government and prepaid health spending.

Total HIV/AIDS spending disaggregated by financing source in 135 low-income and middle-income countries for 2000–17 is shown in figure 1A. For these countries, which included 93.9% (95% UI 91.2–96.3) of the global HIV incidence and 98.3% (98.2–98.4) of global HIV/AIDS deaths in 2017, total spending on HIV/AIDS was \$4.3 billion (3.2–5.9) in 2000 and increased to \$20.2 billion (17.0–25.0) in 2017, increasing at an annualised rate of 9.62% (8.86–10.35) between 2000 and 2017.<sup>23,38</sup> Between 2000 and 2010, DAH for HIV/AIDS increased the fastest of all financing sources, growing at an annualised rate of 22.12%, although this annualised growth rate decreased to –1.64% between 2010 and 2017. In 2017, DAH for HIV/AIDS was \$9.6 billion, with 49.4% being spent on grant administrations and global initiatives. In 2017, government spending on HIV/AIDS reached \$9.7 billion (6.9–13.3), having increased at an annualised rate of 8.86% (8.40–9.34) since 2000. The amount sourced by out-of-pocket spending did not substantially increase, being \$478.5 million (165.6–1069.9) in 2000 and \$589.4 million (214.9–1347.9) in 2017. Total HIV/AIDS spending from

For Financial Global Health data on the Global Health Data Exchange website see <http://ghdx.healthdata.org/series/financing-global-health-fgh>



	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
<b>Global</b>	<b>1048</b> (1034–1062)	<b>1285</b> (1257–1316)	<b>1418</b> (1393–1445)	<b>1816</b> (1766–1871)	<b>9.7%</b> (9.6–9.8)	<b>10.5%</b> (10.1–10.9)	<b>81.3%</b> (80.7–81.8)	<b>82.9%</b> (82.1–83.6)
<b>World Bank income groups</b>								
High-income	5307 (5262–5351)	6596 (6482–6708)	5825 (5777–5872)	7265 (7147–7385)	12.2% (12.1–12.3)	14.0% (13.5–14.4)	86.0% (85.7–86.2)	87.8% (87.5–88.1)
Upper-middle-income	487 (457–520)	808 (740–885)	1053 (995–1118)	1701 (1571–1852)	5.7% (5.3–6.1)	6.8% (6.0–7.6)	66.9% (64.2–69.6)	73.0% (69.6–76.1)
Lower-middle-income	84 (76–93)	127 (114–141)	289 (261–322)	439 (391–496)	3.9% (3.5–4.3)	4.1% (3.6–4.6)	41.6% (36.9–46.1)	45.7% (40.1–51.0)
Low-income	37 (36–39)	45 (42–48)	119 (113–126)	141 (132–152)	5.3% (5.0–5.7)	4.8% (4.4–5.3)	30.9% (28.5–33.6)	36.9% (33.6–40.4)
<b>Central Europe, eastern Europe, and central Asia</b>	<b>538</b> (518–560)	<b>700</b> (672–730)	<b>1332</b> (1276–1390)	<b>1726</b> (1656–1806)	<b>5.9%</b> (5.7–6.2)	<b>6.4%</b> (6.0–6.8)	<b>65.9%</b> (64.1–67.7)	<b>68.6%</b> (66.8–70.5)
<b>Central Asia</b>								
Armenia	403 (364–447)	538 (483–597)	966 (872–1070)	1287 (1156–1428)	9.7% (8.5–10.9)	9.7% (8.3–11.2)	16.0% (12.8–19.6)	17.7% (13.9–21.8)
Azerbaijan	304 (267–343)	368 (321–418)	1268 (1115–1433)	1535 (1339–1747)	6.6% (5.8–7.4)	6.7% (5.6–8.0)	17.4% (13.6–22.0)	18.3% (13.5–23.8)
Georgia	307 (267–354)	521 (449–606)	870 (757–1003)	1477 (1274–1718)	8.0% (6.9–9.3)	10.3% (8.2–12.9)	41.4% (34.5–48.5)	55.8% (48.6–63.0)
Kazakhstan	292 (249–340)	344 (286–411)	949 (811–1105)	1118 (930–1339)	3.4% (2.9–3.9)	3.1% (2.5–3.9)	67.0% (60.2–73.1)	63.8% (55.2–71.5)
Kyrgyzstan	82 (68–99)	99 (80–121)	256 (210–309)	307 (250–376)	6.6% (5.4–7.9)	7.1% (5.6–9.0)	38.9% (30.8–48.1)	44.3% (34.0–55.1)
Mongolia	162 (139–188)	226 (191–267)	563 (484–653)	786 (664–929)	4.2% (3.6–4.9)	4.4% (3.6–5.4)	57.1% (50.0–63.9)	61.1% (53.6–68.0)
Tajikistan	59 (48–74)	68 (54–86)	247 (200–305)	284 (224–358)	7.3% (5.9–9.0)	7.1% (5.4–9.3)	28.5% (20.5–37.3)	29.0% (20.3–39.5)
Turkmenistan	585 (523–656)	768 (683–859)	1417 (1265–1588)	1858 (1654–2079)	8.1% (7.3–9.1)	7.7% (6.6–9.1)	26.7% (21.8–32.3)	25.5% (19.8–32.0)
Uzbekistan	88 (72–106)	124 (101–151)	479 (390–577)	676 (548–823)	5.8% (4.4–7.4)	6.3% (4.4–8.6)	46.0% (36.6–56.0)	50.4% (40.4–60.1)
<b>Central Europe</b>								
Albania	364 (312–428)	607 (516–725)	933 (799–1096)	1554 (1321–1856)	7.3% (6.3–8.7)	9.7% (7.8–12.0)	67.4% (57.5–75.4)	74.5% (66.5–81.2)
Bosnia and Herzegovina	531 (474–590)	838 (741–953)	1325 (1182–1471)	2090 (1848–2378)	9.7% (8.6–10.9)	11.9% (10.1–13.8)	71.2% (66.5–76.0)	76.9% (72.2–80.8)
Bulgaria	713 (657–774)	1161 (1052–1280)	1853 (1707–2012)	3018 (2733–3327)	8.1% (7.5–8.8)	9.6% (8.1–11.1)	52.8% (48.8–57.2)	59.9% (55.5–64.2)
Croatia	900 (824–980)	1165 (1011–1330)	1680 (1539–1831)	2175 (1889–2484)	6.5% (5.9–7.1)	7.1% (6.0–8.3)	89.1% (86.5–91.3)	89.9% (87.4–92.0)
Czech Republic	1585 (1515–1665)	2308 (2120–2529)	2694 (2575–2829)	3922 (3602–4298)	7.2% (6.6–7.9)	8.4% (6.9–10.5)	85.2% (83.5–86.7)	87.1% (85.3–88.7)
Hungary	1107 (1042–1180)	1445 (1343–1559)	2157 (2030–2299)	2816 (2617–3039)	7.0% (6.5–7.4)	7.2% (6.5–8.0)	73.0% (70.6–75.3)	74.1% (71.4–76.7)
Montenegro	672 (518–870)	877 (674–1143)	1555 (1198–2012)	2029 (1559–2645)	8.4% (6.4–10.8)	8.7% (6.5–11.4)	72.0% (62.2–81.1)	73.6% (62.8–82.7)
North Macedonia	433 (342–550)	600 (466–759)	1170 (925–1487)	1623 (1259–2051)	7.6% (6.0–9.7)	8.8% (6.7–11.1)	67.9% (57.7–77.1)	71.7% (62.0–80.3)
Poland	882 (827–945)	1381 (1274–1498)	2003 (1879–2145)	3135 (2894–3402)	6.5% (6.1–6.9)	7.5% (6.6–8.6)	77.1% (74.4–79.6)	80.1% (77.5–82.5)
Romania	585 (535–641)	955 (819–1104)	1320 (1207–1446)	2155 (1849–2492)	5.1% (4.7–5.6)	5.9% (4.8–7.1)	79.0% (74.9–82.4)	81.9% (77.6–85.6)
Serbia	465 (423–512)	666 (596–743)	1163 (1059–1281)	1666 (1492–1858)	7.0% (6.3–8.0)	7.3% (6.1–8.7)	58.2% (53.8–62.9)	59.7% (54.6–64.4)

(Table 2 continues on next page)

	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
Slovakia	1249 (1184-1315)	1640 (1489-1798)	2336 (2214-2459)	3067 (2785-3364)	6.8% (6.5-7.2)	7.1% (6.1-8.2)	81.7% (79.5-83.8)	82.6% (79.9-85.2)
Slovenia	2014 (1913-2120)	2621 (2471-2777)	2974 (2825-3130)	3870 (3649-4101)	8.3% (7.8-8.7)	9.2% (8.5-10.2)	87.8% (86.5-89.0)	88.9% (87.6-90.0)
Eastern Europe								
Belarus	373 (330-422)	470 (387-576)	1173 (1038-1327)	1478 (1215-1813)	5.9% (5.2-6.7)	6.3% (5.0-7.9)	70.3% (64.5-75.4)	72.1% (64.8-78.8)
Estonia	1400 (1338-1462)	1812 (1662-1970)	2164 (2069-2261)	2802 (2569-3045)	6.4% (6.1-6.7)	7.0% (6.2-7.9)	76.7% (74.8-78.5)	78.5% (76.2-80.7)
Latvia	1005 (953-1061)	1278 (1186-1377)	1741 (1651-1839)	2213 (2054-2386)	6.0% (5.7-6.4)	6.3% (5.6-7.1)	57.7% (54.9-60.3)	59.1% (55.5-62.4)
Lithuania	1139 (1081-1201)	1595 (1477-1713)	2171 (2062-2289)	3041 (2816-3267)	6.5% (6.1-6.8)	7.4% (6.4-8.5)	67.8% (65.3-70.1)	71.5% (68.6-73.9)
Moldova	215 (184-250)	288 (245-340)	500 (428-583)	671 (570-792)	7.9% (5.9-11.1)	8.9% (5.8-14.6)	51.8% (44.6-59.5)	56.7% (48.1-64.6)
Russia	574 (526-630)	681 (612-756)	1537 (1409-1688)	1825 (1639-2025)	5.3% (4.8-5.8)	5.4% (4.7-6.3)	59.9% (55.3-64.3)	61.1% (56.4-66.3)
Ukraine	219 (187-255)	248 (212-294)	618 (527-719)	701 (599-828)	6.8% (5.8-8.0)	7.0% (5.7-8.7)	46.1% (39.2-53.7)	48.1% (40.7-56.6)
<b>High-income</b>	<b>5760 (5707-5808)</b>	<b>7106 (6973-7229)</b>	<b>6175 (6121-6225)</b>	<b>7597 (7460-7725)</b>	<b>12.6% (12.5-12.8)</b>	<b>14.5% (14.0-15.0)</b>	<b>86.2% (86.0-86.5)</b>	<b>88.0% (87.7-88.3)</b>
Australasia								
Australia	5195 (5108-5280)	6003 (5868-6154)	5181 (5095-5266)	5987 (5852-6137)	9.9% (9.3-10.8)	10.6% (9.5-12.0)	81.8% (81.1-82.5)	83.3% (82.5-84.1)
New Zealand	4068 (3970-4174)	4755 (4562-4936)	4066 (3969-4172)	4754 (4560-4934)	9.9% (9.6-10.3)	11.1% (10.2-11.9)	86.4% (85.4-87.2)	87.7% (86.7-88.6)
High-income Asia Pacific								
Brunei	690 (634-750)	766 (637-902)	1919 (1764-2085)	2130 (1773-2509)	2.4% (2.2-2.6)	2.6% (2.1-3.2)	94.7% (93.3-95.8)	95.2% (93.6-96.4)
Japan	4290 (4148-4438)	5321 (5037-5597)	4784 (4626-4950)	5934 (5617-6242)	10.7% (10.4-11.1)	12.0% (11.0-12.9)	87.1% (86.3-87.9)	88.6% (87.6-89.5)
Singapore	2739 (2624-2873)	3698 (3314-4168)	4393 (4208-4608)	5931 (5314-6685)	4.5% (4.2-4.8)	5.6% (4.8-6.5)	67.7% (65.9-69.5)	73.7% (70.4-77.0)
South Korea	2118 (2041-2205)	3384 (3118-3613)	2993 (2885-3116)	4782 (4406-5107)	7.2% (6.8-7.6)	10.2% (8.8-11.7)	66.5% (65.0-68.0)	74.6% (72.1-76.8)
High-income North America								
Canada	4919 (4840-5003)	5601 (5451-5762)	5410 (5323-5501)	6159 (5994-6337)	10.7% (10.6-10.9)	12.1% (11.4-12.8)	85.8% (85.1-86.4)	87.3% (86.6-87.9)
Greenland	6559 (6196-6981)	8140 (7578-8745)	4880 (4610-5195)	6057 (5638-6507)	11.8% (10.7-13.2)	13.1% (10.7-16.1)	100.0% (100.0-100.0)	100.0% (100.0-100.0)
USA	10243 (10087-10390)	12734 (12337-13115)	10243 (10087-10390)	12734 (12337-13115)	16.4% (16.2-16.6)	19.1% (17.8-20.4)	88.5% (88.1-88.9)	90.3% (89.8-90.8)
Southern Latin America								
Argentina	907 (830-987)	844 (731-970)	2006 (1837-2184)	1866 (1617-2147)	8.5% (7.7-9.2)	8.7% (7.2-10.5)	85.0% (82.3-87.5)	85.4% (82.2-88.3)
Chile	1379 (1311-1460)	1829 (1712-1955)	2365 (2248-2504)	3136 (2937-3353)	9.2% (8.7-9.7)	10.7% (9.4-12.2)	66.0% (63.7-68.1)	70.4% (68.1-72.6)
Uruguay	1582 (1497-1670)	2048 (1846-2271)	2218 (2099-2341)	2871 (2588-3184)	9.3% (8.8-9.8)	10.3% (8.8-12.1)	82.6% (80.9-84.3)	84.5% (82.3-86.5)
Western Europe								
Andorra	4491 (4310-4675)	5125 (4766-5519)	9712 (9320-10109)	11083 (10308-11936)	7.9% (7.2-8.6)	9.4% (7.6-11.9)	58.6% (56.7-60.6)	63.3% (60.0-66.4)
Austria	5062 (4941-5183)	5602 (5335-5873)	5391 (5263-5521)	5966 (5683-6255)	10.4% (10.1-10.6)	10.9% (10.1-11.7)	80.8% (80.0-81.5)	81.8% (80.7-82.8)

(Table 2 continues on next page)

	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
Belgium	4595 (4475–4727)	5387 (5107–5686)	4995 (4865–5139)	5857 (5552–6182)	10.4% (10.1–10.7)	11.7% (10.9–12.6)	82.3% (81.4–83.2)	84.4% (83.3–85.5)
Cyprus	1184 (1111–1261)	1452 (1350–1566)	1780 (1671–1897)	2184 (2031–2355)	5.1% (4.0–6.7)	5.5% (3.9–8.1)	54.9% (52.0–58.2)	58.7% (55.3–62.0)
Denmark	5933 (5782–6079)	6537 (6302–6768)	5364 (5227–5496)	5911 (5698–6119)	10.1% (9.9–10.4)	10.6% (9.9–11.3)	86.3% (85.7–86.9)	87.1% (86.4–87.8)
Finland	4386 (4253–4523)	4894 (4595–5181)	4298 (4168–4432)	4796 (4503–5077)	9.3% (9.0–9.6)	9.5% (8.8–10.3)	79.6% (78.6–80.6)	80.6% (79.1–82.0)
France	4530 (4455–4600)	5127 (5026–5235)	5100 (5015–5178)	5772 (5658–5893)	11.4% (11.0–11.8)	12.1% (11.2–12.9)	90.6% (89.9–91.3)	91.1% (90.4–91.8)
Germany	5110 (4991–5225)	6162 (5794–6512)	5864 (5727–5995)	7070 (6648–7472)	11.1% (10.9–11.4)	12.5% (11.0–14.1)	87.3% (86.7–87.9)	88.7% (87.8–89.6)
Greece	1571 (1477–1676)	1836 (1664–2020)	2368 (2227–2526)	2768 (2509–3046)	8.3% (7.8–9.0)	8.7% (7.5–10.0)	64.5% (61.5–67.5)	66.8% (63.3–70.2)
Iceland	5538 (5290–5805)	5656 (5264–6079)	4680 (4470–4905)	4780 (4448–5137)	8.3% (7.9–8.7)	8.5% (7.6–9.5)	83.4% (82.4–84.5)	83.5% (82.0–84.9)
Ireland	4979 (4718–5249)	6150 (5670–6662)	5433 (5148–5728)	6711 (6187–7270)	7.0% (6.6–7.4)	7.0% (6.2–8.1)	87.6% (86.5–88.6)	87.8% (86.5–89.1)
Israel	2961 (2864–3068)	3711 (3474–3960)	2710 (2620–2807)	3396 (3178–3623)	7.0% (6.6–7.4)	7.6% (6.6–8.6)	77.4% (76.0–78.7)	79.1% (77.4–80.8)
Italy	2879 (2784–2971)	3130 (2927–3355)	3535 (3419–3649)	3844 (3594–4121)	8.8% (8.4–9.1)	9.2% (8.3–10.4)	76.7% (75.3–77.9)	78.0% (76.2–79.8)
Luxembourg	6066 (5714–6448)	6708 (6057–7439)	5928 (5584–6301)	6555 (5918–7268)	5.4% (5.1–5.8)	6.0% (5.3–6.9)	89.2% (87.7–90.6)	90.2% (88.5–91.7)
Malta	2831 (2731–2939)	4020 (3768–4277)	4353 (4199–4519)	6182 (5794–6577)	9.8% (9.2–10.4)	11.2% (9.9–12.7)	65.0% (63.3–66.6)	69.2% (67.1–71.5)
Netherlands	5143 (4950–5341)	6023 (5611–6462)	5753 (5537–5974)	6738 (6277–7228)	10.2% (9.8–10.5)	10.8% (9.9–11.9)	88.8% (87.9–89.7)	89.4% (88.3–90.5)
Norway	8102 (7841–8368)	9313 (8824–9819)	7959 (7703–8220)	9148 (8668–9646)	10.6% (10.3–11.0)	11.8% (10.6–12.9)	85.8% (85.0–86.7)	87.4% (86.4–88.3)
Portugal	1889 (1797–1988)	2127 (1918–2371)	2744 (2610–2888)	3089 (2785–3444)	8.8% (8.2–9.6)	9.0% (7.7–10.5)	72.5% (70.5–74.2)	72.6% (69.4–75.9)
Spain	2554 (2461–2657)	3110 (2950–3287)	3526 (3398–3668)	4293 (4073–4538)	8.9% (8.6–9.3)	9.9% (8.9–11.0)	76.4% (75.1–77.8)	78.4% (76.8–80.0)
Sweden	5561 (5344–5766)	7007 (6544–7470)	5917 (5685–6135)	7455 (6962–7948)	11.0% (10.6–11.4)	12.7% (11.6–13.8)	84.9% (84.0–85.8)	87.3% (86.2–88.3)
Switzerland	9903 (9669–10151)	11 319 (10796–11888)	7898 (7711–8095)	9027 (8610–9481)	12.1% (11.8–12.5)	13.5% (12.5–14.6)	70.9% (70.0–71.8)	73.8% (72.3–75.2)
UK	3883 (3766–4004)	4623 (4350–4916)	4430 (4297–4569)	5275 (4963–5609)	9.6% (9.3–9.9)	10.9% (9.8–12.1)	84.0% (82.8–85.2)	86.0% (84.7–87.3)
<b>Latin America and Caribbean</b>	<b>589</b> <b>(570–611)</b>	<b>704</b> <b>(682–729)</b>	<b>1189</b> <b>(1150–1234)</b>	<b>1423</b> <b>(1377–1476)</b>	<b>7.4%</b> <b>(7.1–7.7)</b>	<b>8.1%</b> <b>(7.7–8.6)</b>	<b>69.6%</b> <b>(67.8–71.4)</b>	<b>72.8%</b> <b>(71.1–74.6)</b>
Andean Latin America								
Bolivia	217 (184–258)	288 (242–346)	443 (375–525)	587 (493–705)	6.2% (5.3–7.4)	6.8% (5.6–8.2)	70.4% (62.9–77.2)	73.3% (66.5–79.7)
Ecuador	524 (464–591)	565 (496–646)	996 (881–1124)	1074 (943–1229)	8.2% (7.2–9.2)	8.6% (7.3–10.1)	59.2% (53.9–64.6)	61.6% (55.8–67.5)
Peru	330 (283–384)	434 (369–514)	687 (589–799)	903 (768–1069)	4.9% (4.2–5.7)	5.4% (4.3–6.6)	70.6% (64.7–76.3)	73.5% (67.0–79.4)
Caribbean								
Antigua and Barbuda	668 (588–750)	909 (774–1065)	1063 (935–1194)	1447 (1232–1694)	4.2% (3.6–4.9)	4.8% (3.8–5.9)	62.0% (56.7–66.8)	65.6% (59.4–71.4)
The Bahamas	1990 (1863–2113)	2144 (1969–2335)	1967 (1841–2088)	2119 (1946–2308)	6.2% (5.7–6.8)	6.7% (5.6–7.9)	70.8% (68.4–73.1)	71.2% (68.3–74.1)

(Table 2 continues on next page)

	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
Barbados	1180 (1119-1246)	1066 (989-1152)	1224 (1160-1291)	1106 (1025-1195)	6.5% (6.1-7.0)	5.9% (5.2-6.5)	53.1% (50.6-55.6)	46.4% (42.5-50.5)
Belize	287 (247-337)	344 (297-401)	505 (435-593)	605 (522-706)	5.7% (5.0-6.7)	5.9% (4.8-7.3)	73.7% (67.8-78.9)	74.6% (68.9-80.4)
Bermuda	7027 (5973-8208)	8358 (6986-9870)	4430 (3765-5174)	5269 (4404-6222)	6.4% (4.7-9.4)	25.3% (5.0-18.6)	90.1% (86.9-92.8)	91.8% (89.1-94.0)
Cuba	1208 (1129-1304)	1724 (1566-1899)	3262 (3050-3522)	4659 (4231-5131)	11.3% (10.1-12.8)	14.5% (11.7-18.7)	89.8% (87.6-91.7)	91.7% (89.7-93.3)
Dominica	493 (445-550)	644 (536-774)	699 (631-780)	915 (761-1099)	6.6% (5.9-7.4)	6.5% (5.2-8.0)	68.3% (63.3-72.7)	67.5% (60.5-73.6)
Dominican Republic	436 (383-493)	714 (610-828)	1037 (911-1174)	1698 (1450-1969)	5.7% (5.0-6.5)	6.6% (5.3-8.1)	54.5% (48.3-60.6)	60.3% (53.7-66.6)
Grenada	528 (474-593)	642 (553-748)	772 (692-867)	937 (808-1093)	5.0% (4.5-5.6)	4.9% (4.1-6.0)	46.1% (40.6-52.0)	46.9% (39.7-54.8)
Guyana	258 (226-299)	621 (485-793)	456 (399-528)	1097 (855-1400)	5.3% (4.6-6.1)	6.4% (4.8-8.2)	62.6% (55.7-69.1)	70.1% (61.6-78.1)
Haiti	48 (40-57)	50 (42-59)	117 (99-139)	122 (102-145)	6.0% (5.1-7.2)	6.0% (5.0-7.3)	19.3% (14.2-25.3)	17.3% (11.9-23.6)
Jamaica	329 (280-389)	395 (322-482)	583 (497-690)	700 (571-855)	6.2% (5.3-7.3)	7.0% (5.6-8.8)	79.9% (74.5-84.5)	81.5% (76.0-86.2)
Puerto Rico	1276 (1101-1487)	1742 (1499-2034)	1611 (1390-1878)	2199 (1892-2568)	4.1% (3.4-5.0)	5.4% (4.4-6.7)	77.4% (69.9-83.6)	81.9% (75.5-87.2)
Saint Lucia	549 (494-609)	685 (595-781)	743 (668-824)	926 (805-1056)	5.0% (4.5-5.6)	5.6% (4.8-6.6)	51.0% (45.9-56.1)	56.6% (50.1-62.8)
Saint Vincent and the Grenadines	335 (293-382)	439 (377-507)	532 (465-606)	696 (599-806)	4.4% (3.9-5.1)	5.0% (4.2-5.9)	65.5% (59.7-71.7)	67.8% (61.1-73.9)
Suriname	414 (356-477)	526 (439-637)	1044 (899-1203)	1328 (1107-1606)	6.6% (5.6-7.6)	7.7% (6.1-9.5)	73.4% (67.8-78.7)	75.9% (69.9-81.2)
Trinidad and Tobago	1117 (1042-1202)	1400 (1229-1577)	2247 (2096-2419)	2817 (2473-3174)	6.8% (6.3-7.3)	8.1% (6.9-9.5)	59.2% (56.0-62.3)	64.5% (59.6-69.1)
Virgin Islands	1696 (1377-2117)	2011 (1556-2585)	1696 (1377-2117)	2011 (1556-2585)	4.2% (3.4-5.4)	4.8% (3.5-6.7)	75.6% (67.3-83.3)	78.0% (69.5-84.9)
Central Latin America								
Colombia	481 (416-555)	709 (605-827)	1147 (992-1325)	1691 (1445-1973)	7.6% (6.6-8.8)	9.3% (7.8-11.2)	83.6% (79.0-87.1)	86.2% (82.3-89.3)
Costa Rica	944 (869-1026)	1189 (1045-1352)	1408 (1296-1530)	1773 (1559-2017)	8.1% (7.4-8.8)	8.9% (7.6-10.3)	78.2% (75.0-81.4)	80.3% (76.5-83.5)
El Salvador	315 (275-366)	411 (355-482)	650 (568-756)	850 (733-996)	8.0% (6.9-9.4)	9.0% (7.5-10.7)	69.8% (63.9-75.4)	73.5% (68.3-78.7)
Guatemala	265 (227-311)	322 (270-382)	493 (424-580)	600 (504-712)	5.9% (5.0-6.9)	6.0% (5.0-7.3)	44.3% (36.3-52.8)	48.0% (39.9-57.1)
Honduras	185 (155-218)	229 (189-275)	387 (324-457)	479 (396-576)	7.6% (6.3-9.0)	7.7% (6.3-9.3)	47.9% (39.1-57.0)	50.9% (41.9-59.6)
Mexico	562 (502-629)	641 (569-721)	1158 (1035-1297)	1322 (1172-1486)	5.7% (5.0-6.4)	6.1% (5.2-7.2)	59.0% (54.0-63.8)	62.4% (57.0-67.5)
Nicaragua	188 (161-222)	210 (180-247)	516 (441-608)	576 (492-677)	8.7% (7.4-10.3)	10.4% (8.5-12.6)	60.3% (52.5-67.7)	64.3% (56.8-70.9)
Panama	1147 (1067-1235)	1588 (1429-1766)	1883 (1752-2028)	2608 (2346-2899)	7.4% (6.9-8.0)	7.7% (6.6-8.9)	68.6% (65.6-71.7)	69.2% (65.1-73.0)
Venezuela	107 (89-127)	80 (64-101)	555 (466-663)	417 (334-526)	2.2% (1.8-2.8)	2.1% (1.6-2.8)	55.1% (47.0-63.1)	53.9% (43.2-64.3)

(Table 2 continues on next page)

	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
Tropical Latin America								
Brazil	799 (766-834)	942 (909-978)	1505 (1443-1570)	1774 (1712-1841)	9.2% (8.8-9.6)	10.1% (9.2-11.2)	72.4% (69.3-75.3)	75.6% (72.8-78.2)
Paraguay	389 (338-453)	528 (451-619)	937 (813-1091)	1271 (1087-1490)	7.6% (6.0-10.0)	8.8% (6.5-12.6)	55.8% (49.2-62.6)	61.1% (54.8-67.4)
<b>North Africa and Middle East</b>	<b>353 (339-367)</b>	<b>426 (404-451)</b>	<b>1055 (1012-1104)</b>	<b>1263 (1198-1337)</b>	<b>5.3% (5.1-5.5)</b>	<b>6.4% (6.0-6.9)</b>	<b>68.0% (66.2-69.8)</b>	<b>72.6% (70.8-74.4)</b>
Afghanistan	50 (37-65)	53 (40-68)	203 (154-265)	219 (165-281)	9.9% (7.5-13.0)	9.2% (6.6-12.5)	6.7% (4.5-9.1)	7.9% (5.5-11.1)
Algeria	265 (232-304)	297 (249-350)	988 (866-1133)	1106 (928-1304)	6.6% (5.8-7.6)	7.3% (6.1-8.8)	69.1% (62.3-75.0)	72.0% (65.6-78.1)
Bahrain	1230 (1169-1292)	1386 (1287-1483)	2422 (2300-2543)	2728 (2534-2920)	4.9% (4.7-5.2)	5.9% (5.0-6.9)	70.6% (68.2-73.1)	74.0% (71.0-76.8)
Egypt	147 (121-178)	189 (153-228)	675 (552-815)	863 (702-1044)	5.5% (4.3-6.7)	5.3% (4.0-6.7)	39.6% (30.3-49.7)	38.4% (28.7-49.1)
Iran	555 (495-618)	580 (516-648)	1763 (1574-1966)	1845 (1642-2061)	8.1% (7.2-9.3)	10.1% (8.2-12.3)	58.7% (53.4-64.4)	65.2% (59.8-70.4)
Iraq	195 (166-230)	258 (214-306)	609 (520-719)	808 (670-958)	3.4% (2.9-4.0)	4.0% (3.1-5.1)	32.4% (26.1-39.0)	41.3% (32.4-49.9)
Jordan	293 (251-344)	348 (291-427)	643 (551-754)	764 (639-938)	6.7% (5.8-7.9)	7.2% (5.8-8.8)	66.9% (60.1-73.3)	69.0% (62.1-75.6)
Kuwait	1556 (1400-1725)	1630 (1391-1890)	3640 (3277-4036)	3815 (3256-4422)	4.9% (4.2-5.5)	5.5% (4.3-7.0)	85.9% (83.6-87.8)	86.4% (83.5-88.9)
Lebanon	935 (847-1028)	1123 (962-1301)	1481 (1341-1628)	1777 (1523-2059)	10.2% (8.8-11.9)	10.6% (8.2-13.6)	66.5% (62.2-70.7)	68.6% (63.1-73.7)
Libya	466 (392-548)	436 (348-546)	821 (690-966)	768 (614-963)	9.5% (3.6-20.4)	11.9% (3.8-23.1)	73.2% (66.4-78.8)	78.0% (71.0-84.2)
Morocco	171 (145-205)	225 (187-270)	471 (398-564)	620 (516-742)	5.3% (4.4-6.3)	5.7% (4.6-7.0)	44.4% (36.3-53.6)	47.6% (38.9-57.0)
Oman	664 (624-711)	626 (549-731)	1702 (1600-1822)	1606 (1406-1875)	4.0% (3.5-4.4)	4.0% (3.1-5.0)	93.7% (92.0-95.0)	93.1% (91.1-94.7)
Palestine	365 (300-436)	492 (393-615)	139 (115-167)	188 (150-235)	10.9% (8.9-13.0)	12.1% (9.5-15.5)	57.0% (48.1-65.9)	63.3% (53.6-71.7)
Qatar	1958 (1780-2155)	3458 (2762-4411)	3750 (3410-4128)	6624 (5291-8451)	2.8% (2.6-3.1)	5.0% (3.9-6.4)	91.9% (90.3-93.3)	94.4% (92.6-95.9)
Saudi Arabia	1206 (1107-1310)	1786 (1577-2080)	3046 (2796-3307)	4511 (3983-5253)	5.2% (4.8-5.7)	8.0% (6.7-9.7)	83.8% (81.7-85.8)	88.8% (86.9-90.7)
Sudan	54 (43-68)	56 (45-70)	315 (250-395)	327 (261-407)	5.8% (4.2-8.1)	6.4% (4.3-9.4)	26.5% (18.9-35.7)	30.5% (21.5-40.7)
Syria	57 (46-70)	75 (59-91)	922 (744-1133)	1210 (958-1478)	5.7% (4.3-7.4)	5.9% (4.3-8.3)	45.9% (35.8-56.6)	48.0% (36.9-58.9)
Tunisia	238 (203-280)	326 (278-383)	916 (782-1078)	1253 (1070-1472)	7.4% (6.3-8.7)	9.1% (7.6-10.9)	60.6% (52.4-68.2)	66.5% (59.1-73.9)
Turkey	379 (333-429)	486 (403-587)	1228 (1079-1392)	1578 (1307-1904)	4.2% (3.7-4.8)	4.8% (3.9-5.8)	82.2% (77.5-86.3)	84.4% (79.5-88.2)
United Arab Emirates	1485 (1380-1600)	1925 (1633-2240)	2630 (2444-2834)	3408 (2892-3966)	3.7% (3.3-4.1)	5.2% (4.1-6.5)	81.1% (78.3-83.7)	84.9% (81.5-88.0)
Yemen	50 (42-62)	58 (48-70)	123 (101-150)	141 (116-171)	5.4% (3.8-7.5)	5.8% (3.9-8.6)	9.6% (7.1-12.4)	17.6% (13.1-23.5)
<b>South Asia</b>	<b>62 (51-77)</b>	<b>104 (85-130)</b>	<b>236 (192-291)</b>	<b>396 (321-493)</b>	<b>3.4% (2.8-4.2)</b>	<b>3.6% (2.8-4.5)</b>	<b>35.3% (26.2-45.4)</b>	<b>39.6% (29.4-49.4)</b>
Bangladesh	40 (31-52)	68 (52-87)	107 (83-136)	178 (138-231)	2.5% (1.9-3.2)	2.5% (1.8-3.4)	21.1% (14.9-27.9)	21.4% (15.3-28.3)
Bhutan	108 (90-129)	144 (109-185)	316 (262-378)	420 (320-542)	3.2% (2.6-3.9)	2.8% (2.0-3.7)	79.2% (72.9-84.4)	77.1% (68.4-83.9)

(Table 2 continues on next page)



	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
India	69 (54-87)	119 (94-152)	265 (209-336)	456 (360-583)	3.5% (2.8-4.5)	3.7% (2.8-4.8)	36.5% (25.6-48.0)	41.1% (29.3-52.4)
Nepal	50 (40-63)	79 (62-100)	162 (128-204)	255 (199-321)	5.5% (4.3-7.0)	5.6% (4.1-7.4)	31.6% (22.7-42.4)	35.7% (25.7-47.2)
Pakistan	37 (29-46)	49 (38-62)	159 (126-199)	211 (164-267)	2.8% (2.2-3.5)	2.9% (2.2-3.6)	33.0% (23.5-43.5)	36.1% (25.4-47.2)
<b>Southeast Asia, east Asia, and Oceania</b>	<b>365 (329-406)</b>	<b>730 (645-825)</b>	<b>757 (686-839)</b>	<b>1499 (1336-1683)</b>	<b>4.9% (4.4-5.5)</b>	<b>6.3% (5.3-7.4)</b>	<b>64.2% (59.7-68.8)</b>	<b>72.4% (67.6-76.7)</b>
East Asia								
China	455 (400-517)	984 (850-1132)	875 (769-994)	1891 (1634-2176)	5.1% (4.4-5.7)	6.6% (5.4-8.0)	64.5% (59.2-69.8)	73.4% (67.8-78.2)
North Korea	77 (60-96)	87 (68-110)	45 (35-56)	51 (39-64)	5.6% (4.3-7.0)	5.9% (4.4-7.8)	63.8% (52.5-73.6)	66.7% (55.5-76.0)
Taiwan (province of China)	1477 (1312-1677)	1903 (1677-2172)	3270 (2905-3711)	4213 (3713-4808)	6.2% (5.5-7.1)	6.9% (5.7-8.4)	69.0% (64.9-73.7)	72.2% (67.9-76.5)
Oceania								
American Samoa	694 (572-841)	711 (573-869)	694 (572-841)	711 (573-869)	5.5% (4.5-6.8)	6.0% (4.7-7.8)	78.4% (71.0-85.0)	79.7% (72.2-86.3)
Federated States of Micronesia	141 (119-166)	224 (185-270)	136 (115-160)	215 (178-259)	4.1% (3.3-5.0)	5.9% (4.4-7.8)	84.3% (80.7-87.5)	88.9% (85.8-91.5)
Fiji	198 (160-243)	255 (200-322)	356 (288-438)	459 (360-580)	3.5% (2.7-4.5)	3.8% (2.8-5.0)	78.6% (71.7-84.5)	79.5% (72.5-85.5)
Guam	1468 (1143-1903)	1607 (1236-2088)	1468 (1143-1903)	1607 (1236-2088)	3.7% (2.9-4.9)	4.1% (3.1-5.8)	75.1% (65.2-83.2)	77.2% (68.4-84.6)
Kiribati	214 (188-246)	234 (195-282)	290 (255-334)	317 (264-382)	14.1% (12.2-16.3)	15.0% (12.0-18.6)	59.3% (52.9-65.3)	61.2% (53.0-68.7)
Marshall Islands	416 (370-472)	554 (468-648)	408 (362-462)	544 (459-636)	11.1% (9.6-12.9)	12.9% (10.4-15.8)	67.2% (62.3-71.9)	71.5% (65.9-76.7)
Northern Mariana Islands	752 (585-992)	806 (614-1071)	752 (585-992)	806 (614-1071)	2.4% (1.9-3.2)	2.9% (2.1-4.1)	73.4% (63.2-81.8)	76.1% (66.8-84.1)
Papua New Guinea	54 (44-64)	71 (57-87)	82 (67-98)	108 (87-133)	2.1% (1.6-2.5)	2.6% (1.9-3.3)	73.5% (67.6-78.7)	78.0% (72.1-83.0)
Samoa	222 (194-254)	248 (209-293)	298 (259-339)	332 (280-393)	5.0% (4.3-5.7)	5.3% (4.2-6.4)	78.7% (74.2-82.8)	79.6% (74.3-84.2)
Solomon Islands	119 (103-135)	127 (95-175)	119 (103-135)	128 (95-175)	5.6% (4.8-6.5)	5.4% (3.8-7.6)	60.9% (55.2-65.8)	60.6% (48.7-72.7)
Tonga	218 (196-243)	277 (235-329)	291 (261-325)	369 (314-439)	5.1% (4.4-5.8)	5.0% (3.9-6.3)	65.4% (61.2-69.5)	69.3% (63.5-74.7)
Vanuatu	98 (82-118)	117 (89-154)	89 (74-107)	107 (81-140)	3.0% (2.5-3.6)	3.1% (2.3-4.1)	67.7% (61.5-73.4)	70.5% (61.5-78.7)
Southeast Asia								
Cambodia	83 (67-101)	129 (103-157)	236 (190-288)	368 (294-448)	5.7% (4.6-6.9)	5.8% (4.5-7.3)	25.7% (19.0-33.6)	28.4% (20.6-37.9)
Indonesia	120 (94-152)	215 (166-277)	405 (316-511)	722 (558-931)	3.2% (2.5-4.0)	4.0% (3.0-5.2)	60.8% (49.1-72.0)	68.7% (58.5-77.6)
Laos	58 (48-70)	83 (67-103)	173 (143-210)	247 (201-309)	2.4% (1.9-3.1)	2.3% (1.6-3.4)	36.9% (28.8-46.7)	36.5% (27.4-46.5)
Malaysia	409 (353-475)	673 (575-790)	1190 (1029-1382)	1960 (1674-2299)	3.9% (3.4-4.6)	4.9% (4.1-5.9)	62.5% (56.6-68.7)	69.0% (63.3-75.1)
Maldives	988 (905-1081)	1638 (1430-1884)	1479 (1355-1618)	2452 (2141-2821)	8.1% (6.4-10.1)	10.6% (7.4-14.8)	79.7% (76.5-82.7)	83.9% (80.4-86.9)

(Table 2 continues on next page)

	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
Mauritius	606 (541-677)	969 (855-1106)	1309 (1170-1462)	2094 (1846-2389)	5.7% (5.1-6.4)	6.9% (5.9-8.2)	50.9% (45.7-56.3)	57.9% (52.2-63.5)
Myanmar	52 (41-66)	87 (68-111)	279 (220-357)	470 (365-597)	4.4% (3.4-5.6)	4.4% (3.3-5.9)	16.3% (11.4-22.1)	18.6% (11.5-27.0)
Philippines	133 (107-168)	204 (165-256)	374 (300-472)	573 (463-719)	4.4% (3.5-5.6)	4.8% (3.8-6.2)	44.5% (34.6-55.8)	50.0% (39.3-61.6)
Sri Lanka	152 (124-182)	204 (164-247)	534 (437-641)	718 (579-871)	3.9% (3.2-4.8)	4.1% (3.2-5.1)	48.8% (39.4-58.4)	49.2% (38.9-59.2)
Seychelles	754 (697-817)	992 (846-1161)	1394 (1288-1510)	1834 (1563-2146)	4.6% (4.3-5.0)	5.0% (4.2-6.0)	74.3% (70.8-77.8)	76.7% (72.2-81.3)
Thailand	271 (229-326)	388 (326-465)	702 (593-843)	1005 (844-1205)	3.8% (3.2-4.5)	4.4% (3.6-5.4)	88.1% (84.1-91.4)	89.7% (86.1-92.7)
Timor-Leste	86 (69-106)	114 (89-144)	197 (158-243)	261 (204-331)	3.6% (2.9-4.4)	4.0% (3.0-5.3)	72.5% (66.0-78.6)	77.7% (71.0-83.6)
Vietnam	135 (111-164)	208 (167-257)	399 (327-484)	614 (492-758)	5.5% (4.5-6.7)	5.6% (4.3-7.3)	52.6% (43.5-62.7)	53.6% (43.7-64.5)
<b>Sub-Saharan Africa</b>	<b>81 (75-87)</b>	<b>92 (85-99)</b>	<b>204 (190-218)</b>	<b>232 (216-250)</b>	<b>5.2% (4.8-5.6)</b>	<b>5.1% (4.7-5.6)</b>	<b>54.0% (50.6-57.2)</b>	<b>55.8% (52.0-59.5)</b>
Central sub-Saharan Africa								
Angola	90 (73-112)	82 (64-105)	205 (166-254)	186 (145-238)	2.9% (2.3-3.6)	2.7% (2.0-3.5)	62.6% (52.7-72.2)	58.6% (46.8-70.2)
Central African Republic	21 (18-23)	26 (22-31)	36 (32-41)	45 (38-54)	4.7% (4.0-5.6)	4.7% (3.6-6.0)	14.6% (10.9-19.1)	21.0% (12.7-32.0)
Congo (Brazzaville)	59 (48-71)	64 (49-84)	175 (143-210)	191 (147-248)	2.7% (2.0-3.5)	2.6% (1.7-3.7)	46.8% (36.3-56.2)	44.4% (32.7-56.9)
Democratic Republic of the Congo	19 (16-22)	21 (17-26)	30 (26-36)	35 (28-42)	3.7% (3.0-4.5)	3.7% (2.6-4.9)	20.5% (13.6-29.5)	24.2% (16.1-34.9)
Equatorial Guinea	299 (257-345)	352 (304-409)	711 (611-821)	837 (723-972)	2.8% (2.4-3.2)	3.1% (2.3-4.1)	20.9% (16.1-26.9)	29.2% (22.7-37.5)
Gabon	289 (253-338)	386 (328-460)	702 (612-819)	936 (795-1115)	3.6% (3.2-4.2)	4.3% (3.5-5.3)	65.6% (59.6-71.4)	70.6% (64.3-76.3)
Eastern sub-Saharan Africa								
Burundi	30 (26-36)	31 (26-39)	70 (60-84)	74 (60-93)	9.0% (7.5-10.9)	9.4% (7.4-12.0)	35.5% (26.3-46.7)	37.7% (26.4-50.7)
Comoros	74 (60-91)	85 (70-104)	150 (122-185)	173 (142-211)	5.2% (4.0-6.5)	5.3% (4.0-7.0)	14.9% (10.4-20.4)	19.5% (13.3-26.8)
Djibouti	57 (48-69)	63 (51-79)	104 (87-124)	113 (92-142)	2.5% (1.7-3.6)	2.4% (1.5-3.7)	56.8% (47.8-65.0)	55.6% (44.6-66.2)
Eritrea	24 (20-30)	33 (26-40)	33 (27-41)	44 (35-54)	5.2% (2.7-10.2)	5.8% (2.3-17.2)	21.9% (16.0-28.8)	26.8% (17.9-37.1)
Ethiopia	31 (25-38)	43 (34-57)	81 (67-101)	114 (89-149)	4.0% (3.1-5.1)	3.3% (2.3-4.7)	39.4% (28.8-51.5)	45.8% (33.3-58.9)
Kenya	96 (78-120)	126 (100-161)	185 (150-230)	243 (192-310)	5.3% (4.3-6.7)	5.1% (3.9-6.7)	54.1% (43.3-63.5)	60.1% (49.6-69.8)
Madagascar	22 (18-27)	28 (22-36)	81 (65-100)	102 (80-130)	4.8% (3.7-6.0)	5.3% (3.9-7.1)	58.1% (48.7-67.8)	64.7% (54.5-74.1)
Malawi	45 (41-51)	46 (40-55)	151 (136-169)	154 (132-184)	11.9% (10.5-13.7)	9.7% (7.8-12.3)	29.1% (22.5-37.2)	34.3% (25.5-44.4)
Mozambique	34 (32-36)	36 (32-42)	91 (85-98)	98 (85-114)	6.9% (6.4-7.4)	5.1% (4.2-6.2)	23.7% (19.5-28.9)	35.5% (27.4-44.4)
Rwanda	45 (39-53)	60 (46-78)	133 (114-157)	175 (136-229)	6.2% (5.3-7.4)	5.3% (3.9-7.3)	46.2% (37.4-54.9)	63.8% (53.8-73.5)

(Table 2 continues on next page)

	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
Somalia	6 (5-7)	6 (5-8)	14 (12-16)	14 (12-17)	4.7% (3.9-5.6)	4.7% (3.8-5.9)	19.3% (14.7-24.9)	19.3% (14.2-25.0)
South Sudan	32 (29-35)	29 (25-33)	217 (201-237)	197 (173-229)	9.7% (6.1-13.2)	7.5% (3.3-11.9)	14.5% (10.9-19.0)	18.5% (15.2-22.1)
Tanzania	43 (38-49)	50 (41-61)	129 (115-147)	151 (124-185)	4.2% (3.5-5.1)	3.8% (2.7-5.7)	35.7% (29.0-43.5)	44.7% (34.7-55.0)
Uganda	44 (37-51)	54 (44-64)	149 (127-173)	184 (151-219)	6.5% (5.4-7.8)	5.9% (4.5-7.6)	19.5% (13.9-25.9)	30.1% (21.6-40.2)
Zambia	66 (58-76)	67 (55-83)	210 (182-241)	212 (173-264)	5.0% (4.3-5.8)	4.7% (3.7-6.0)	40.8% (33.2-49.1)	44.0% (33.2-56.0)
Southern sub-Saharan Africa								
Botswana	449 (393-516)	738 (633-859)	1017 (890-1170)	1671 (1433-1946)	5.9% (5.1-6.8)	7.5% (6.1-9.1)	89.6% (87.8-91.4)	93.0% (91.3-94.4)
eSwatini	289 (249-340)	327 (270-399)	773 (666-909)	873 (722-1067)	7.1% (6.1-8.3)	6.9% (5.6-8.5)	59.2% (52.5-65.7)	58.9% (50.7-67.7)
Lesotho	129 (113-147)	172 (148-199)	336 (296-383)	448 (387-519)	10.5% (9.0-12.3)	12.0% (9.6-15.0)	53.4% (47.2-59.6)	58.4% (51.1-65.0)
Namibia	553 (488-629)	630 (546-729)	1100 (971-1252)	1253 (1085-1450)	9.4% (8.2-10.9)	10.1% (8.2-12.4)	83.8% (80.6-86.6)	84.7% (81.2-87.5)
South Africa	533 (466-612)	673 (573-793)	1195 (1044-1372)	1509 (1285-1777)	8.6% (7.5-9.9)	10.5% (8.9-12.4)	89.9% (87.2-92.2)	91.4% (89.0-93.4)
Zimbabwe	75 (62-92)	71 (56-91)	285 (235-349)	270 (213-347)	9.0% (6.5-12.8)	8.3% (5.5-12.8)	54.1% (44.9-63.2)	51.1% (39.1-62.8)
Western sub-Saharan Africa								
Benin	35 (29-41)	41 (33-51)	97 (81-116)	114 (92-143)	3.7% (2.6-4.9)	3.2% (2.1-4.8)	27.8% (20.4-36.9)	33.0% (24.2-43.7)
Burkina Faso	41 (33-49)	55 (43-68)	116 (95-141)	156 (122-194)	6.0% (5.0-7.3)	6.0% (4.7-7.6)	47.3% (36.7-57.3)	54.7% (43.9-65.4)
Cameroon	60 (48-75)	75 (59-95)	158 (125-198)	196 (155-248)	4.1% (3.2-5.1)	3.9% (3.0-5.0)	15.9% (10.8-22.2)	17.9% (11.5-26.0)
Cape Verde	162 (135-194)	237 (191-292)	349 (291-417)	509 (411-627)	4.8% (4.0-5.7)	5.3% (4.2-6.5)	67.1% (58.8-74.3)	70.8% (61.8-77.9)
Chad	29 (23-37)	32 (25-41)	83 (66-106)	93 (72-118)	3.9% (2.8-5.3)	3.7% (2.5-5.1)	24.9% (17.5-33.3)	27.3% (18.1-38.7)
Côte d'Ivoire	74 (58-92)	98 (76-128)	195 (153-241)	259 (200-336)	4.8% (3.8-5.9)	4.6% (3.4-6.0)	44.5% (33.1-57.1)	49.3% (36.5-61.5)
The Gambia	43 (40-47)	42 (37-49)	162 (151-176)	158 (138-183)	7.1% (5.1-10.6)	5.3% (3.3-8.9)	20.3% (16.1-25.9)	20.5% (15.7-26.7)
Ghana	66 (53-81)	111 (87-138)	208 (168-254)	349 (275-434)	3.7% (2.7-5.3)	4.4% (2.9-6.6)	46.5% (36.0-57.0)	58.8% (47.9-69.5)
Guinea	45 (36-55)	60 (47-77)	110 (90-135)	149 (116-188)	4.4% (3.4-5.8)	4.2% (3.0-5.9)	23.7% (15.6-33.5)	29.7% (19.6-41.7)
Guinea-Bissau	60 (49-73)	71 (56-89)	142 (116-172)	168 (132-211)	8.3% (6.7-10.3)	7.9% (6.1-10.2)	10.5% (6.9-15.0)	14.1% (8.7-20.6)
Liberia	65 (56-75)	74 (62-88)	130 (112-151)	148 (124-177)	10.6% (7.6-15.3)	11.2% (7.1-18.7)	17.8% (12.2-25.2)	20.7% (13.1-30.6)
Mali	32 (27-37)	38 (31-46)	85 (73-100)	102 (83-125)	3.4% (2.6-4.3)	3.2% (2.2-4.3)	31.1% (24.1-39.1)	40.2% (29.8-51.7)
Mauritania	61 (50-74)	80 (65-99)	213 (175-257)	279 (226-345)	5.0% (4.0-6.2)	4.8% (3.6-6.2)	40.5% (31.1-50.2)	43.0% (33.1-54.0)
Niger	26 (21-33)	33 (26-41)	69 (56-86)	87 (68-108)	6.8% (5.5-8.5)	7.0% (5.3-9.0)	30.6% (22.3-39.9)	40.5% (30.2-51.2)
Nigeria	78 (62-96)	85 (68-107)	212 (170-262)	233 (185-291)	3.5% (2.8-4.3)	3.4% (2.6-4.4)	16.0% (11.2-21.6)	17.4% (11.2-25.5)

(Table 2 continues on next page)

	Health spending per capita, 2019 US\$		Health spending per capita, 2019 purchasing-power parity-adjusted \$		Total health spending per GDP, %		Total government health spending and prepaid private spending per total health spending, %	
	2017	2030	2017	2030	2017	2030	2017	2030
(Continued from previous page)								
São Tomé and Príncipe	113 (100–128)	136 (103–181)	184 (162–208)	221 (167–295)	5.8% (5.0–6.6)	5.6% (4.1–7.6)	46.3% (39.3–52.9)	50.5% (37.3–65.0)
Senegal	65 (55–78)	76 (62–92)	170 (142–203)	197 (161–240)	4.8% (4.0–5.8)	4.4% (3.5–5.4)	29.2% (22.1–37.2)	30.8% (22.4–41.3)
Sierra Leone	70 (58–84)	82 (67–101)	223 (185–268)	260 (213–322)	13.5% (11.2–16.3)	12.5% (9.8–16.0)	21.1% (14.1–29.9)	22.1% (14.2–31.9)
Togo	41 (33–51)	54 (43–69)	111 (89–137)	147 (116–186)	6.4% (5.1–7.9)	6.6% (5.2–8.5)	26.3% (18.2–35.8)	34.8% (24.5–46.0)

Estimates in parentheses are 95% uncertainty intervals. Venezuela estimates are presented as 2014 US\$. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. GDP=Gross Domestic Product.

**Table 2: Total health spending, by World bank income group, and GBD super-region, 2017 and 2030**

prepaid private sources increased from \$140.6 million (26.9–430.0) in 2000 to \$395.8 million (93.2–1166.8) in 2017.

Since 2015, spending in low-income and middle-income countries to prevent and treat HIV/AIDS has increased from \$10.6 billion (95% UI 8.3–13.9) to \$12.0 billion (9.1–16.2) in 2017, primarily due to increases in government spending. Despite this growth, increases in spending levels have not been even across countries. 39 countries (including Zimbabwe and Kenya) spent less on HIV/AIDS in 2017 than in 2015, primarily because of reductions in DAH; a full list of country estimates is on the Global Health Data Exchange website.

The amount of HIV/AIDS spending per prevalent case for each region in 2017, and the fraction that is from each financing source is shown in figure 1B. Although more was spent in total in sub-Saharan Africa (\$7660.6 million [95% UI 6736.2–8883.6]), HIV/AIDS spending per prevalent case was highest in the GBD super-region north Africa and the Middle East (\$2987 [95% UI 1857–4589] per prevalent case), followed by Latin American and the Caribbean (\$1702 [1113–2640] per prevalent case). Per prevalent case, spending was lowest in south Asia (\$297 [216–413] per prevalent case) and sub-Saharan Africa (\$296 [263–338] per prevalent case). Although domestic governments contributed the most to spending on HIV/AIDS in most regions, financing was dominated in sub-Saharan Africa by DAH (54.9% [48.0–61.5] of total HIV/AIDS spending; figure 1B).


SDG indicator 3.3.1 is to eliminate HIV/AIDS incidence. Change in HIV/AIDS incidence and HIV/AIDS spending per capita for each low-income and middle-income country for 2000–17 is shown in figure 1C. For all but one (Venezuela) of 135 countries, HIV/AIDS spending per capita has increased since 2000. 73 countries had reductions in HIV/AIDS incidence, while 62 had increases in incidence. While sub-Saharan Africa has had major decreases in HIV incidence and increases in spending per capita, other super-regions have had increases in HIV incidence since 2015.

Total tuberculosis spending disaggregated by source in 135 low-income and middle-income countries for 2000–17 is shown in figure 2A. These countries comprise 98.4% (95% UI 98.3–98.4) global tuberculosis incidence in 2017 and 98.7% (98.7–98.8) of tuberculosis deaths for the same year.<sup>23,38</sup> For these countries, spending on tuberculosis increased at an annualised rate of 3.87% (3.04–4.64), from \$5.7 billion (5.2–6.5) in 2000 to \$10.9 billion (10.3–11.8) in 2017. Government spending amounted to \$6.9 billion (6.5–7.5) or 63.5% (59.2–66.8) of all tuberculosis spending in 2017 and increased annually by 5.06% (4.43 to 5.72) since 2000. Although DAH for tuberculosis increased at an even faster rate (15.91%), the amount in 2017 was \$1.7 billion, of which 33.5% was spent on administrative costs and global initiatives. The amount of tuberculosis spending that was out-of-pocket has decreased steadily since 2000, as more tuberculosis cases have been treated in the public system. In 2000, an estimated \$2.4 billion (1.9–3.1) was spent out-of-pocket on tuberculosis, while in 2017, \$2.1 billion (1.6–2.7) was spent. Spending on tuberculosis from prepaid private sources was \$246.9 million (171.9–368.7) in 2000 and \$225.0 million (184.1–280.7) in 2017. Since the start of the SDGs in 2015, 87 of 135 low-income and middle-income countries we analysed increased their spending on tuberculosis (for more details see the WHO Global Health Data Exchange).


The amount of tuberculosis spending per incident case for each GBD super-region in 2017 (excluding the high-income region), and the fraction that is from each financing source are shown in figure 2B. Total spending was greatest in the central Europe, eastern Europe, and central Asia (appendix p 10), which also had the largest spending per incident case (\$13 955 [95% UI 12 659–15 341]). The lowest spending per incident case was in sub-Saharan Africa (\$526 [493–569]) and south Asia (\$616 [489–787]). In most super-regions in 2017, domestic governments were the source of more than 75% of total tuberculosis funding. In south Asia, the dominant sources of spending were governments (44.1% [32.3–54.8]) and

**Figure 1: HIV/AIDS spending in low-income and middle-income countries**

(A) Total spending on HIV/AIDS by financing source, 2000 to 2017. (B) Breakdown of financing sources of HIV/AIDS spending and total HIV/AIDS spending per prevalent case, by GBD super-region, in 2017 with pie size proportional to spending per prevalent case of HIV/AIDS. (C) Annualised rates of change in HIV/AIDS prevalence and HIV/AIDS spending per capita, with each arrow showing one country moving from 2000 to 2017. Data are from all World Bank low-income and middle-income countries and spending estimates are presented in 2019 \$US. Venezuela's spending is presented in 2014 \$US. Administrative expenses that are only shown in panel A and reflect the operational expense of deploying the grant that is accrued in the donor country (eg, salaries of headquarters office staff). AFG=Afghanistan. ARM=Armenia. AZE=Azerbaijan. BFA=Burkina Faso. BLR=Belarus. BWA=Botswana. CHN=China. CMR=Cameroon. COM=Comoros. CUB=Cuba. DZA=Algeria. FSM=Federated States of Micronesia. GAB=Gabon. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. GEO=Georgia. GMB=The Gambia. KHM=Cambodia. LBR=Liberia. MHL=Marshall Islands. MMR=Myanmar. MNG=Mongolia. MOZ=Mozambique. MUS=Mauritius MWI=Malawi. NER=Niger. PAK=Pakistan. RUS=Russia. RWA=Rwanda. SWZ=eSwatini. TJK=Tajikistan. TLS=Timor-Leste. VEN=Venezuela. YEM=Yemen. ZWE=Zimbabwe.







**Figure 2: Tuberculosis spending in low-income and middle-income countries** (A) Spending on tuberculosis by financing source, 2000 to 2017. (B) Breakdown of financing sources of tuberculosis spending and total tuberculosis spending for each incident case, by GBD super-region, in 2017, with pie size proportional to spending per prevalent case of tuberculosis. (C) Annualised rates of change in tuberculosis incidence and tuberculosis spending per capita, with each arrow showing one country moving from 2000 to 2017. Data are from all World Bank low-income and middle-income countries and spending estimates are presented in 2019 US\$. Venezuela's spending is presented in 2014 US\$. Administrative expenses that are only shown in panel A reflect the operational expense of deploying the grant that is accrued in the donor country (eg, salaries of headquarters office staff). ALB=Albania. ARM=Armenia. AZE=Azerbaijan. BGR=Bulgaria. BLR=Belarus. CHN=China. CIV=Côte d'Ivoire. CRI=Costa Rica. CUB=Cuba. DZA=Algeria. ECU=Ecuador. ERI=Eritrea. GAB=Gabon. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. GNB=Guinea-Bissau. GRD=Grenada. GTM=Guatemala. IRQ=Iraq. JOR=Jordan. KAZ=Kazakhstan. LBY=Libya. LKA=Sri Lanka. LSO=Lesotho. MDA=Moldova. MKD=North Macedonia. MMR=Myanmar. MOZ=Mozambique. MRT=Mauritania. NAM=Namibia. NER=Niger. NGA=Nigeria. NIC=Nicaragua. PAK=Pakistan. PER=Peru. PHL=Philippines. PNG=Papua New Guinea. PRK=North Korea. RUS=Russia. RWA=Rwanda. SSD=South Sudan. STP=São Tomé and Príncipe. SWZ=eSwatini. TCD=Chad. TJK=Tajikistan. TLS=Timor-Leste. TUR=Turkey. VEN=Venezuela. YEM=Yemen.

out-of-pocket spending (42.8% [30.0–56.8]), while in sub-Saharan Africa, governments (39.0% [35.4–42.7]) and DAH (28.8% [26.6–30.7]) are the main sources of funding for tuberculosis.

SDG indicator 3.3.2 is to eliminate tuberculosis incidence. Change in tuberculosis incidence and tuberculosis spending per capita for each low-income and middle-income country for 2000–17 is shown in figure 2C. 122 (90%) of 135 low-income and middle-income countries saw decreases in tuberculosis incidence between 2000 and 2017, with the few exceptions being primarily in sub-Saharan Africa and southeast Asia, east Asia, and Oceania. We saw substantial variation in spending patterns over time, with 113 (84%) of 135 countries increasing spending and 22 (16%) countries decreasing tuberculosis spending per capita. For tuberculosis, in eSwatini, Lesotho, and Nicaragua, we observed a more than 12% annualised rate of change in per capita spending with varying annualised rates of change in incidence (0.89% decrease for eSwatini, 0.04% increase for Lesotho, 2.14% decrease for Nicaragua; figure 2C).

Total malaria spending disaggregated by financing source in 106 countries with local malaria transmission since 2000 is shown in figure 3A. 102 (96%) of 106 countries are low-income or middle-income countries, and 99.98% (95% UI 99.97–99.98) of malaria deaths in 2017 were in these 106 countries.<sup>38</sup> Spending on malaria increased annually by 7.96% (95% UI 8.20–7.74) from \$1.4 billion (1.3–1.5) in 2000 to \$5.1 billion (4.9–5.4) in 2017. Domestic governments have been a relatively stable source of funding for malaria, with spending changing from \$0.8 billion (0.7–0.9) in 2000 to \$1.6 billion (1.5–1.8) in 2017. Meanwhile, spending from DAH and out-of-pocket spending have substantially increased, comprising 48.7% (46.3–50.8) and 16.1% (13.4–19.8) of total spending in 2017. DAH contributed \$2.5 billion in 2017, while \$0.8 billion (0.7–1.0) was contributed by out-of-pocket spending.

Since 2015, spending on malaria increased from \$4.8 billion (95% UI 4.6–5.1) to \$5.1 billion (4.9–5.4) in 2017, and spending in 63 (59%) of 106 countries increased (figure 3). Increases in prepaid-private spending, out-of-pocket spending, and DAH all contributed to these increases.

The amount of malaria spending per capita for each region in 2017 and the fraction that is from each financing source are shown in figure 3B. The spending per capita in sub-Saharan Africa was \$3.21 (95% UI 3.01–3.44), which was much larger than in the other malaria endemic GBD super-regions. The least spending per capita was in central Europe, eastern Europe, and central Asia (\$0.10 [0.08–0.13]). Government spending constitutes the most spending on malaria in the super-regions of central Europe, eastern Europe, and central Asia; Latin America and Caribbean; north Africa and the Middle East; and southeast Asia, east Asia, and Oceania.


DAH made up a larger share of the spending on malaria for sub-Saharan Africa than the other communicable diseases tracked in this study.

SDG indicator 3.3.3 is to eliminate malaria incidence. Change in malaria incidence and malaria spending per capita for each of 102 malaria endemic low-income and middle-income country for 2000–17 are shown in figure 3C. This figure highlights the 13 of 102 countries that have eliminated malaria since 2000 and relatively constant malaria spending per capita. Additionally, all but three of the remaining 93 remaining malaria endemic low-income and middle-income countries—Djibouti, Niger, and Venezuela—have seen reductions in malaria incidence. Meanwhile, malaria spending per capita has increased in 78 of 106 malaria endemic low-income and middle-income countries with the largest spending increases in sub-Saharan Africa. We observed that in Myanmar and eSwatini, per capita spending increased at an annualised rate of more than 15% from 2000 to 2017, and annualised incidence rate of the disease decreased by more than 10% (figure 3C).

Change in universal health coverage service coverage index and pooled health spending per capita for 2000–17 across all 195 countries and territories is shown in figure 4. We saw a strong association between increases in pooled health spending per capita and progress towards universal health coverage, with countries in the GBD super-regions of sub-Saharan Africa, south Asia, and southeast Asia, east Asia and Oceania making large gains in universal health coverage as pooled spending per capita increased. Since 2015, spending increased in 166 (85%) of 195 countries and universal health service coverage increased in 188 (96%) countries (data not shown).


Although economic development is associated with reducing the domestic health financing burden that is funded by out-of-pocket spending, considerable variation exists in this association (figure 5A). For any one level of GDP per capita, a sizeable range of the fraction of domestic health spending is financed by out-of-pocket spending, suggesting that economic development does not solely determine the transition away from household financing. Additionally, large variation exists across countries in the association between rate of change in the fraction of domestic health spending that is out-of-pocket and the rate of change in the proportion of households with catastrophic health expenditure (figure 5B). A reliance on domestic government, prepaid, and pooled health financing is a means towards achieving universal health coverage and financial risk protection. Globally, this fraction contributing to universal health coverage ranges from 6.7% (95% UI 4.5–9.1) in Afghanistan to 100% (100–100) in Greenland (for more details see the WHO Global Health Data Exchange).

In 2019, \$40.6 billion of DAH was disbursed and increased at an annualised rate of 1.74% since 2015 (figure 6A). Over 1990 to 2019, reproductive and



**Figure 3: Malaria spending in 106 malaria endemic countries**

(A) Total spending on malaria by financing source, 2000 to 2017. (B) Breakdown of financing source of malaria spending and the total malaria spending for each incident case, by GBD super-region, in 2017, with pie size proportional to spending per prevalent case of malaria. (C) Annualised rates of change in malaria incidence and malaria spending per capita, with each arrow showing one country moving from 2000 to 2017. Data are from all malaria-endemic World Bank low-income and middle-income countries and spending estimates are presented in 2019 US\$. Venezuela's spending is presented in 2014 US\$. Administrative expenses are only shown in panel A reflect the operational expense of deploying the grant that is accrued in the donor country (eg, salaries of headquarters office staff). In panel C, dashed lines indicate countries that have eliminated malaria. World Bank low- and middle-income countries that have eliminated malaria since 2000 are Argentina, Armenia, Azerbaijan, Costa Rica, Georgia, Iraq, Kyrgyzstan, Morocco, Paraguay, Sri Lanka, Syria, Tajikistan, Turkey, and Uzbekistan. AFG=Afghanistan. BGD=Bangladesh. BTN=Bhutan. BWA=Botswana. CHN=China. COL=Colombia. COM=Comoros. CPV=Cape Verde. DJI=Djibouti. DZA=Algeria. ETH=Ethiopia. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. GMB=The Gambia. GNB=Guinea-Bissau. GTM=Guatemala. HND=Honduras. KHM=Cambodia. LBR=Liberia. MMR=Myanmar. MYS=Malaysia. NER=Niger. NPL=Nepal. PHL=Philippines. PRK=North Korea. SLV=El Salvador. SOM=Somalia. STP=São Tomé and Príncipe. SWZ=eSwatini. THA=Thailand. TLS=Timor-Leste. VEN=Venezuela. YEM=Yemen.



**Figure 4: Annualised rate of change in universal health service coverage index and annualised rate of change in pooled health spending per capita, 2000 to 2017** Data are for 195 countries in territories, by GBD super-region. Spending estimates are presented in 2019 US\$, and pooled health spending is the sum of government spending, prepaid private spending, and development assistance for health. Each arrow shows one country moving from 2000 to 2017. Spending estimates are presented in 2019 US\$. AFG=Afghanistan. AZE=Azerbaijan. CHN=China. COD=Democratic Republic of the Congo. ERI=Eritrea. ETH=Ethiopia. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. GEO=Georgia. GUM=Guam. KHM=Cambodia. LAO=Laos. LSO=Lesotho. MMR=Myanmar. RWA=Rwanda. TCD=Chad. TLS=Timor-Leste. VEN=Venezuela. YEM=Yemen.

maternal health has consistently received substantial contributions, starting from \$1.7 billion in 1990 to \$4.8 billion in 2019. This change constitutes an annualised rate of change of 3.65%. However, since in 2004, DAH for HIV/AIDS has received the highest contributions of all health focus areas, peaking at \$12.0 billion in 2012.

The annualised rate of change across the health focus areas for the time periods associated with the Millennium Development Goals (MDGs) and the SDGs are shown in figure 6B. Between 2000 and 2015, DAH increased by 7.75%, with disbursements for malaria increasing by 18.32%, for tuberculosis by 16.18%, and for HIV/AIDS by 13.02%. For the period 2015–19, the annualised growth rate for tuberculosis spending is 5.75%, for HIV/AIDS is 2.18%, and for malaria is 1.43%. Other key health focus areas that are funding progress on specific SDG indicators have had annual rates of change for 2015–19 of 4.25% for non-communicable diseases, 2.53% for reproductive and maternal health, and 0.66% for newborn and child health. The annualised growth

rate of DAH for other infectious diseases has decreased for the period 2015–19, which is driven by the increased contributions that went towards the Ebola outbreak in 2014–15 and the subsequent re-alignment of resources after the Ebola crisis.


Based on past trends and associations, we estimate that an additional \$238 (95% UI 209–267) per capita will be available for health globally in 2030 compared with 2017, with persistent disparities in spending between countries and across income groups (table 2). The proportion of health spending from pooled sources is expected to increase from 81.6% (81.6–81.7) in 2015 to 83.1% (82.8–83.3) in 2030. In high-income countries, health spending is expected to continue to increase, with expected annualised growth rates of 1.93% (1.77–2.10), reaching \$6596 (6482–6708) per capita in 2030. For high-income countries, government and prepaid private spending as the financing sources of health is expected to increase to 87.8% (87.5–88.1) of total health spending. Health spending growth is expected to be fastest in lower-middle-income countries, where the

annual growth rate is expected to be 4.38% (4.13–4.66) between 2018 and 2030, with per-capita spending reaching \$127 (114–141). In these countries, government spending is also expected to be the financing source with the fastest growth (5.12% [4.73–5.54]), with government and prepaid private health spending making up 45.7% (40.1–51.0) of overall spending. For countries currently considered to be low income by The World Bank, resources for health are expected to grow annually by 4.13% (3.75–4.55) between 2018 and 2030, although in per capita terms, annualised health spending growth is expected to be only 1.52% (1.15–1.93), reaching \$45 (42–48) per capita in 2030.

### Discussion

Disease-specific spending studies are valuable because they can provide policy makers and planners with insights into the financial burden created by specific diseases. This knowledge can subsequently be used in prioritisation, planning, budgeting, and evaluation of programmes; programme and policy interventions and development; and ultimately in better management of health systems. Our analysis quantified health sector spending and health spending on HIV/AIDS, tuberculosis, and malaria relative to outcomes, which are all priorities under SDG3. We also examined future availability of resources for health. Our results highlight that, globally, total health spending has increased since the state of the SDGs in 2015, reaching \$7.9 trillion (7.8–8.0) in 2017, and is expected to increase to \$11.0 trillion (10.7–11.2) by 2030, although with substantial disparity across countries. In 2017, in low-income and middle-income countries, an estimated \$20.2 billion was spent on HIV/AIDS, \$10.9 billion was spent on tuberculosis, and \$5.1 billion was spent on malaria in endemic countries. Although both domestic government and DAH spending, has increased across these three diseases, the accompanied changes in outcomes have varied. We found that malaria had the most consistent decreases in outcomes across countries as spending has increased.


These health spending estimates enable further examination of the existing publicly available estimates of the financing required to achieve the SDG3 targets. Existing



**Figure 5: Out-of-pocket spending for health**

(A) Out-of-pocket spending as a share of total health spending, in 2017. (B) Change in proportion of households with catastrophic health spending versus change in proportion of domestic health spending that is out-of-pocket, 2000–17. Spending estimates are presented in 2019 US\$. In panel A, estimates are plotted against GDP per capita with a loess regression line (span=0.95) and 95% uncertainty intervals shaded in grey. Timor-Leste is excluded from panel B because the World Bank estimates for 2000–17 showed that no households in the country had catastrophic health spending. BLR=Belarus. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. GDP=Gross Domestic Product. HTI=Haiti. IRL=Ireland. JOR=Jordan. LAO=Laos. MDV=Maldives. MNG=Mongolia. NER=Niger. RWA=Rwanda. SRB=Serbia. THA=Thailand. ZMB=Zambia.





**Figure 6: Development assistance for health** (A) Changes in development assistance for health by health focus area, 1990–2019. (B) Annualised rate of change in development assistance for health by health focus area, 2000–15 and 2015–19. Estimates are presented in billions of 2019 US\$. GBD=Global Burden of Diseases, Injuries, and Risk Factors study. \*Data for 2018 and 2019 are preliminary estimates based on budget data and estimation.

estimates suggest that the additional annual financing required to achieve SDG3 in 67 low-income and middle-income countries is \$274 billion (progress scenario in which the attainment of goals is limited by countries' health systems existing absorptive capacity), and to reach health system targets for SDG3 including scale-up of health workforce and infrastructure is \$371 billion.<sup>28</sup> Stenberg and colleagues estimated that to achieve SDG3 in 67 low-income and middle-income countries, the corresponding per capita spending would need to increase to \$249 per year (progress scenario) or \$271 per year (ambitious scenario) by 2030.<sup>28</sup> Another study by the Sustainable Development Solutions Network that included 59 low-income countries estimated that to achieve SDG3 would cost, approximately \$225 billion between 2019 and 2030, with a per capita cost of \$86 for low-income countries and \$134 for lower-middle-income countries as the minimum needed to provide care consistent with basic human rights.<sup>39</sup> A few other studies have also generated estimates of the resources needed using different methods.<sup>36,37,40</sup> Our estimates suggest that 81 (60%) of 135 low-income and middle-income countries have not yet reached health spending of \$249 per capita, and our projections suggest that 75 countries might still not reach these goals by 2030.

Although these financing goals can be benchmarks to encourage more spending and increased health system efficiency, they do not ensure that SDG3 will be achieved. Ultimately, costing estimates like these need to be continuously improved to make them locally relevant and price appropriate, with realistic assumptions about

health system inefficiency and the distribution of spending in a country, and to incorporate any challenges associated with preventing and treating disease in difficult to reach contexts.

For all three diseases for which a complete and comparable series of spending estimates exist in low-income and middle-income countries—HIV/AIDS, tuberculosis, and malaria—comparing the relative contributions from the different financing sources highlights interesting patterns. Governments contribute substantially across all three diseases. This observation is important because domestic resource mobilisation has received renewed interest as a key strategy for generating resources to finance the SDGs.<sup>4</sup> While DAH contributions to malaria and HIV/AIDS are substantial, contributions to tuberculosis are smaller. This pattern brings into light long-standing concerns and debate regarding the allocation of DAH especially across health focus areas.<sup>41–43</sup> These concerns and debate include whether the current criteria that rely mainly on a country's level of development are the most appropriate to use for allocation, donor preference for implementing vertical programmes with short-term measurable effects, and prioritisation of such diseases to broader health system challenges. Also, the relative dependence on household out-of-pocket spending across the three diseases is notable, with the proportion of out-of-pocket spending for tuberculosis and malaria being much larger than the proportion for HIV/AIDS. Changes in policy, such as making HIV treatment available and free to all, has transformed management of care for HIV/AIDS and its by-source

funding distribution. Previous studies have shown that high out-of-pocket spending promotes health impoverishment.<sup>17,44,45</sup> Hence, targeted efforts, such as public education campaigns on enrolment in national health insurance or free provision of services where appropriate, aimed at increasing the share of national health spending that is financed through pooled resources might improve financial protection.

The distribution of health spending by source across different regions also highlights heterogeneous health financing patterns for the three diseases globally. For some geographical regions (eg, Central Europe, eastern Europe, and central Asia, and sub-Saharan Africa), governments carry the primary burden of providing resources for these diseases, while in other regions (eg, southeast Asia, east Asia, and Oceania, and south Asia) the pattern of financing changes with the type of disease. Similarly, health spending globally has distinct patterns. In the high-income GBD super-region, spending by governments dominates, while in other super-regions, such as south Asia and sub-Saharan Africa, DAH and out-of-pocket spending are prominent. Preferably, resources for financing health care should be pooled to restrict the risk of health impoverishment for the population and delays in accessing needed care. Resources for financing health care could be pooled through government facilitation of the development of viable prepaid mandatory insurance programmes.

The association between spending on health and health outcomes is of interest to many audiences, especially because of the increases in spending on health that have been observed in the past two decades with the adoption of the MDGs and now the SDGs. Our results highlight a nuanced and complex picture regarding the link between health spending and its associated effect on outcomes—here, disease-specific outcomes. Although substantial reductions in the incidence of some diseases were observed as spending increased in some countries, in others decreases in the incidence of other disease were minimal or even increases in incidence were seen. For example, for malaria, we observed that in Myanmar and eSwatini, per-capita spending increased at an annualised rate of more than 15% from 2000 to 2017, and the annualised incidence rate decreased by more than 10%, while for tuberculosis, in eSwatini, Lesotho, and Nicaragua, we observed a more than 12% annualised rate of growth in per-capita spending with varying annualised rates of change in incidence (0·89% decrease for eSwatini, 0·04% increase for Lesotho, 2·14% decrease for Nicaragua). Because these findings are not causal, interest in understanding this link between spending on health and health outcomes is strong and more efforts would be needed to understand the drivers of success.

Overall, these results highlight the continued importance of domestic resource mobilisation in securing the financing required for the SDGs and the health-related SDGs in particular. Although donor contributions will be

necessary to meet spending targets in some low-income countries, governments were an important source of funding in the broader health system and among the three disease areas for which data were available. For most middle-income countries, the aspiration is that national economic growth will also bolster what resources are allocated to the health sector by the government. Furthermore, although DAH will continue to be needed in some low-income countries, a continued need for and value in DAH provision to cover so-called global public goods or common goods for health exists (such as pandemic preparedness or research and development for neglected tropical diseases).<sup>35,46–52</sup> This continued need is because the multisectoral nature of the SDGs and the increasingly interconnected world we live in present shared global challenges that need to be addressed beyond the individual country support framework that DAH has typically addressed.

In addition to the need to generate more resources to finance the health-related SDGs, the need to efficiently use existing resources should be highlighted. The comparison of the annualised rates of change of pooled health spending per capita and universal health coverage index highlighted some of the best performers at each level of development. For example, Myanmar and Georgia show annualised growth in per-capita-pooled spending of more than 13%, which was associated with 2·14% annualised growth in universal health coverage index in Myanmar and 0·05% in Georgia. Peer-to-peer country learning might facilitate the transfer of best practices in both the delivery and administration of the health sector in countries that are not yet performing optimally with their available resources. The second annual Universal Health Coverage Financing Forum organised by the World Bank highlighted strategies such as strategic purchasing, improvement in data management systems, and organisational management that can be adopted to promote better efficiency for health.<sup>53</sup> However, while important health gains can probably be made by increasing efficiency and investing in allied sectors, our future health spending estimates indicate that spending is expected to remain low in many countries, which raises concerns about the viability of reaching crucial SDG3 goals in those countries. In such countries, additional efforts to mobilise revenue, such as tax reforms where appropriate, are needed to ensure that adequate resources are available to support the achievement of the SDG3 goals.

Furthermore, the nuanced evidence on the scale-up of spending and improvements in health outcomes suggest a complex association between spending and health outcomes. This complexity highlights that, although more resources are likely to be needed to achieve SDG3, other constraints such as inefficient resource allocation, weak governance systems, drug shortages, and inadequate health workforce and management systems for health information in the broader health system that constrain

improvements in health outcomes will need to be addressed to achieve the SDG3 targets.

Finally, this study has also shown the gaps in current resource tracking efforts as they relate to the health-related SDGs. Most comparative data are available for the three diseases we studied but little comparable data on financing for most of the remaining indicators are available. This pattern might reflect funding priorities spurred by the MDGs. Given the broader orientation of the goals under the SDGs, a need exists for increased understanding on the financing for the other SDG3 targets.

Future research areas might include efforts targeted at financing health-related SDGs, such as hepatitis B, neglected tropical diseases, and non-communicable diseases, including substance abuse, alcohol use, road injury, adolescent birth, hazardous chemicals, and air, water, and soil pollution. Additionally, studies that aim to determine the types of spending that promote improvements in outcomes are needed to guide resource investments.

This study has several limitations. First, the data we used reported using different research units for each SDG3 indicator. HIV/AIDS, tuberculosis, and malaria spending estimates were available for a subset of total countries. As such, although the available data is meaningful and contributes to our knowledge of spending on the SDGs, a directly comparable analysis of global spending inclusive of all countries on these indicators is currently constrained by gaps in the available data. Also, multiple competing cost estimates exist, and so the existing financing targets that we found for comparison with our spending estimates often differed in geographical scope, methods, and currency. These comparisons require precise and context-specific costing estimates that incorporate realistic levels of efficacy. Second, some of the input data on global health spending used to generate total health spending estimates had questionable annual growth trends or did not provide direct information about the sources of the data. We used modelling methods to enable incorporation of these data but we acknowledge that challenges exist in terms of the quality of the available global health spending data. Additionally, we provided UIs for the estimates to provide information on the quality and precision of the estimates generated. Third, while the use of keywords to isolate relevant health focus and programme areas for our DAH analysis is the best existing strategy for a comprehensive effort, it relies heavily on the project description provided in the databases and in some instances might not accurately reflect what the funds actually contributed to. Fourth, presenting spending at disease level might not be the level of aggregation that is most relevant for ministries of health and disaggregating at facility level (primary, secondary, and tertiary) or at expenditure-item level (staff, commodities) might be more readily useful to them. We plan to provide estimates that include these levels of disaggregation in the near future. Notably, our analysis of spending and outcomes was not designed to detect

causality, but was primarily a descriptive analysis of the associations between these two metrics. Therefore, our findings should not be interpreted as causal. Fifth, when forecasting health expenditures, we are unable to incorporate fundamentally new and different policies or innovations that are outside of the bounds of the observed data. Current estimates do not directly account for mass migration due to conflict and are only able to be incorporated on the basis of these events being reflected in the underlying covariates.

Furthermore, due to data availability, our analyses mainly covered four SDG priority areas. Spending on several SDG3 targets, including hepatitis B incidence, substance abuse, chemical and environmental pollution do not yet have a comparable set of spending estimates, which would prohibit analyses. Ideally, estimates on DAH and domestic spending on all the priority areas under SDG3 will provide a more comprehensive picture. Nonetheless, we believe that the data and estimates we have provided are an adequate first step in monitoring the spending for these key SDG3 areas.

Finally, while each set of spending estimates is consistent and comparable on its own, the input data vary enough between diseases that the spending estimates between diseases are not perfectly comparable. For example, the HIV/AIDS and malaria government spending estimates are modelled on the basis of tabulated data, generally reporting total spending or budgets, while government spending estimates for tuberculosis and for out-of-pocket malaria and tuberculosis spending were based on taking the product of unit cost and service coverage estimates. These distinct estimation strategies will drive some differences, with unit cost and service coverage estimates not comprehensively including inefficient spending that does not yield increases in service coverage.

As of publication of this Article, health systems throughout the world are stretched thin addressing the effects of coronavirus disease 2019 (COVID-19). Over the past 5 months it has become increasingly clear that, although not yet fully realised, both the health and economic losses caused by this novel coronavirus will be immense. Because these costs are not yet known in full and because the pandemic is ongoing, the effects of COVID-19 have not been considered in the financing projections reported in this Article. If these costs lead to reductions in health spending as nations focus inward on economic woes or if these costs can be a catalyst for investment in robust public health systems and in shared vision of global health security remains to be seen.

The link between spending and changes in outcomes remains complex, and realistic country-specific spending targets for most SDG3 indicators do not exist. Understanding how much is being spent and where crucial gaps exist are the first steps in providing evidence for a global dialogue about how much investment is needed for health, where it should come from, and where and on whom it should be spent. Using the resources

available more efficiently and addressing broader health system constraints to service delivery, such as inadequate health information management systems, weak governance systems, shortages in health workforce and pharmaceuticals, are crucial if substantial progress is to be made towards achieving the health-related SDGs. A key tenet underlying the SDG era is that “no one is left behind”. To achieve this goal by 2030, current efforts must expand to include the tracking of spending in all of these areas, increasing resources, and spending those resources more efficiently.

#### Global Burden of Disease Health Financing Collaborator Network

Angela E Micah\*, Yanfang Su\*, Steven D Bachmeier, Abigail Chapin, Ian E Cogswell, Sawyer W Crosby, Brandon Cunningham, Anton C Harle, Emilie R Maddison, Modhurima Moitra, Maitreyi Sahu, Matthew T Schneider, Kyle E Simpson, Hayley N Stutzman, Golsum Tsakalos, Rahul R Zende, Bianca S Zlavog, Cristiana Abbafati, Zeleke Hailemariam Abebo, Hassan Abolhassani, Michael R M Abrigo, Muktar Beshir Ahmed, Rufus Olusola Akinyemi, Khurshid Alam, Saqib Ali, Cyrus Alinia, Wahid Alipour, Syed Mohamed Aljunid, Ali Almasi, Nelson Alvis-Guzman, Robert Ancuceanu, Tudorel Andrei, Catalina Liliana Andrei, Mina Anjomshoa, Carl Abelardo T Antonio, Jalal Arabloo, Morteza Arab-Zozani, Olatunde Aremu, Desta DeBalkie Atnafu, Marcel Ausloos, Leticia Avila-Burgos, Martin Amogre Ayanore, Samad Azari, Tesleem Kayode Babalola, Mojtaba Bagherzadeh, Atif Amin Baig, Ahad Bakhtiari, Maciej Banach, Srikanta K Banerjee, Till Winfried Bärnighausen, Sanjay Basu, Bernhard T Baune, Mohsen Bayati, Adam E Berman, Reshmi Bhageerathy, Pankaj Bhardwaj, Mehdi Bohluli, Reinhard Busse, Lucero Cahuana-Hurtado, Luis L A Alberto Cámara, Carlos A Castañeda-Orjuela, Ferrán Catalá-López, Muge Cevik, Vijay Kumar Chattu, Lalit Dandona, Rakhi Dandona, Mostafa Dianatinasab, Hoa Thi Do, Leila Doshmangir, Maha El Tantawi, Sharareh Eskandarieh, Firooz Esmaeilzadeh, Anwar Faraj, Farshad Farzadfar, Florian Fischer, Nataliya A Foigt, Nancy Fullman, Mohamed M Gad, Mansour Ghafourifard, Ahmad Ghashghaee, Asadollah Gholamian, Salime Goharinezhad, Ayman Grada, Hassan Haghparast Bidgoli, Samer Hamidi, Hilda L Harb, Edris Hasanpoor, Simon I Hay, Delia Hendrie, Nathaniel J Henry, Claudiu Herteliu, Michael K Hole, Mehdi Hosseinzadeh, Sorin Hostiuc, Tanvir M Huda, Ayesha Humayun, Bing-Fang Hwang, Olayinka Stephen Ilesanmi, Usman Iqbal, Seyed Sina Irvani, Sheikh Mohammed Shariful Islam, M Mofizul Islam, Mohammad Ali Jahani, Mihajlo Jakovljevic, Spencer L James, Zohre Javaheri, Jost B Jonas, Farahnaz Joukar, Jacek Jerzy Józwiak, Miik Jürisson, Rohollah Kalthor, Behzad Karami Matin, Salah Eddin Karimi, Gbenga A Kayode, Ali Kazemi Karyani, Yohannes Kinfu, Adnan Kisa, Stefan Kohler, Hamidreza Komaki, Soewarta Kosen, Anirudh Kotlo, Ai Koyanagi, G Anil Kumar, Dian Kusuma, Van C Larsingh, Anders O Larsson, Savita Lasrado, Shaun Wen Huey Lee, Lee-Ling Lim, Rafael Lozano, Hassan Magdy Abd El Razek, Mokhtar Mahdavi Mahdavi, Shokofeh Maleki, Reza Malekzadeh, Fariborz Mansour-Ghanaei, Mohammad Ali Mansournia, Lorenzo Giovanni Mantovani, Gabriel Martinez, Seydeh Zahra Masoumi, Benjamin Ballard Massenburg, Ritesh G Menezes, Endalkachew Worku Mengesha, Tuomo J Meretoja, Atte Meretoja, Tomislav Mestrovic, Neda Milevska Kostova, Ted R Miller, Andreea Mirica, Erkin M Mirrakhimov, Masoud Moghadaszadeh, Bahram Mohajer, Efat Mohamadi, Aso Mohammad Darwesh, Abdollah Mohammadian-Hafshejani, Reza Mohammadpourhodki, Shafiu Mohammed, Farnam Mohebi, Ali H Mokdad, Shane Douglas Morrison, Jonathan F Mosser, Seyyed Meysam Mousavi, Moses K Muriithi, Saravanan Muthupandian, Chaw-Yin Myint, Mehdi Naderi, Ahamarshan Jayaraman Nagarajan, Cuong Tat Nguyen, Huong Lan Thi Nguyen, Justice Nonvignon, Jean Jacques Noubiap, In-Hwan Oh, Andrew T Olagunju, Jacob Olusegun Olusanya, Bolajoko Olubukunola Olusanya, Ahmed Omar Bali,

Obinna E Onwujekwe, Stanislav S Otstavnov, Nikita Otstavnov, Mayowa Ojo Owolabi, Jagadish Rao Padubidri, Raffaele Palladino, Songhomitra Panda-Jonas, Anamika Pandey, Maarten J Postma, Sergio I Prada, Dimas Ria Angga Pribadi, Mohammad Rabiee, Navid Rabiee, Fakher Rahim, Chhabi Lal Ranabhat, Sowmya J Rao, Priya Rathi, Salman Rawaf, David Laith Rawaf, Lal Rawal, Reza Rawassizadeh, Aziz Rezapour, Siamak Sabour, Mohammad Ali Sahraian, Omar Mukhtar Salman, Joshua A Salomon, Abdallah M Samy, Juan Sanabria, João Vasco Santos, Milena M Santric Milicevic, Bruno Piassi Sao Jose, Miloje Savic, Falk Schwendicke, Subramanian Senthilkumaran, Sadaf G Sepanlou, Edson Serván-Mori, Hamidreza Setayesh, Masood Ali Shaikh, Aziz Sheikh, Kenji Shibuya, Mark G Shrimme, Biagio Simonetti, Jasvinder A Singh, Pushpendra Singh, Valentin Yurievich Skryabin, Amin Soheili, Shahin Soltani, Simona Cătălina Ștefan, Rafael Tabarés-Seisdedos, Roman Topor-Madry, Marcos Roberto Tovani-Palone, Bach Xuan Tran, Ravensara Travillian, Eduardo A Undurraga, Pascual R Valdez, Job F M van Boven, Tommi Juhani Vasankari, Francesco S Violante, Vasily Vlassov, Theo Vos, Charles D A Wolfe, Junjie Wu, Sanni Yaya, Wahid Yazdi-Feyzabadi, Paul Yip, Naohiro Yonemoto, Mustafa Z Younis, Chuanhua Yu, Zoubida Zaidi, Sojib Bin Zaman, Mikhail Sergeevich Zastrozhin, Zhi-Jiang Zhang, Yingxi Zhao, Christopher J L Murray, Joseph L Dieleman.

\*Contributed equally.

#### Affiliations

Institute for Health Metrics and Evaluation (A E Micah PhD, Y Su ScD, S D Bachmeier MS, A Chapin BA, I E Cogswell BS, S W Crosby BA, B Cunningham MA, A C Harle BA, E R Maddison BS, M Moitra MPH, M Sahu MSPH, M T Schneider MPH, K E Simpson BS, H N Stutzman BA, G Tsakalos MS, R Zende BTEch, B S Zlavog BS, Prof L Dandona MD, Prof R Dandona PhD, N Fullman MPH, Prof S I Hay FMedSci, N J Henry BS, S L James MD, Prof R Lozano MD, Prof A H Mokdad PhD, J F Mosser MD, R Travillian PhD, Prof T Vos PhD, J Wu BA, Prof C J L Murray PhD, Prof J L Dieleman PhD), Department of Health Metrics Sciences, School of Medicine (Prof S I Hay FMedSci, Prof R Lozano MD, Prof A H Mokdad PhD, Prof T Vos PhD, Prof C J L Murray PhD, Prof J L Dieleman PhD), Department of Surgery, Division of Plastic and Reconstructive Surgery (B B Massenburg MD, S D Morrison MD), University of Washington, Seattle, WA, USA; Department of Juridical and Economic Studies (C Abbafati PhD), La Sapienza University, Rome, Italy; Department of Public Health (Z H Abebo MSc), Arba Minch University, Arba Minch, Ethiopia; Department of Laboratory Medicine (H Abolhassani PhD), Karolinska University Hospital, Huddinge, Sweden; Department of Epidemiology and Biostatistics (M Mansournia PhD), Department of Health Management and Economics (S Mousavi PhD), Department of Health Policy and Management (A Bakhtiari PhD), Digestive Diseases Research Institute (Prof R Malekzadeh MD, S G Sepanlou MD), Health Equity Research Center (E Mohamadi PhD), Iran National Institute of Health Research (F Mohebi MD), Metabolomics and Genomics Research Center (F Rahim PhD), Multiple Sclerosis Research Center (S Eskandarieh PhD, B Mohajer MD, Prof M Sahraian MD), Non-communicable Diseases Research Center (F Farzadfar MD, B Mohajer MD, F Mohebi MD), Research Center for Immunodeficiencies (H Abolhassani PhD), Tehran University of Medical Sciences, Tehran, Iran; Research Department (M R M Abrigo PhD), Philippine Institute for Development Studies, Quezon City, Philippines; Department of Epidemiology (M B Ahmed MPH), Jimma University, Jimma, Ethiopia; Australian Center for Precision Health (M B Ahmed MPH), University of South Australia, Adelaide, SA, Australia; Department of Community Medicine, College of Medicine (O S Ilesanmi PhD), Institute for Advanced Medical Research and Training (R O Akinyemi PhD, Prof M O Owolabi DrM), University of Ibadan, Ibadan, Nigeria; Murdoch Business School (K Alam PhD), Murdoch University, Perth, WA, Australia; Department of Information Systems, College of Economics and Political Science (S Ali PhD), Sultan Qaboos University, Muscat, Oman; Department of Health Care Management and Economics (C Alinia PhD), Urmia University of Medical Science, Urmia, Iran; Health Economics



Department (V Alipour PhD), Health Management and Economics Research Center (V Alipour PhD, J Arabloo PhD, S Azari PhD, A Ghashghaee BSc, A Rezapour PhD), Preventive Medicine and Public Health Research Center (S Goharinezhad PhD), Student Research Committee, Faculty of Health Management and Information Sciences Branch (A Ghashghaee BSc), Iran University of Medical Sciences, Tehran, Iran; Department of Health Policy and Management (Prof S M Aljunid PhD), Kuwait University, Safat, Kuwait; International Centre for Casemix and Clinical Coding (Prof S M Aljunid PhD), National University of Malaysia, Bandar Tun Razak, Malaysia; Clinical Research Development Center, Taleghani and Imam Ali Hospital (S Maleki MSc, M Naderi PhD), Department of Environmental Health Engineering (Prof A Almasi PhD), Department of Public Health (A Kazemi Karyani PhD), Research Center for Environmental Determinants of Health (Prof B Karami Matin PhD), A Kazemi Karyani PhD, S Soltani PhD), Kermanshah University of Medical Sciences, Kermanshah, Iran; Research Group in Health Economics (Prof N Alvis-Guzman PhD), Universidad de Cartagena, Cartagena de Indias, Colombia; Research Group in Hospital Management and Health Policies (Prof N Alvis-Guzman PhD), Universidad de la Costa, Barranquilla, Colombia; Department of Legal Medicine and Bioethics (S Hostiuc PhD), Faculty of Pharmacy (Prof R Ancuceanu PhD), Carol Davila University of Medicine and Pharmacy, Bucharest, Romania (C Andrei PhD); Department of Statistics and Econometrics (A Mirica PhD, Prof T Andrei PhD, Prof M Ausloos PhD, Prof C Herteliu PhD) and Department of Management (S Ștefan PhD), Bucharest University of Economic Studies, Bucharest, Romania; Social Determinants of Health Research Center (M Anjomshoa PhD), Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Health Policy and Administration (C A T Antonio MD), University of the Philippines Manila, Manila, Philippines; Department of Applied Social Sciences (C A T Antonio MD), Hong Kong Polytechnic University, Hong Kong, China; Social Determinants of Health Research Center (M Arab-Zozani PhD), Birjand University of Medical Sciences, Birjand, Iran; School of Health Sciences (O Aremu PhD), Birmingham City University, Birmingham, UK; Department of Health System and Health Economics (D D Atnafu MPH), Department of Reproductive Health and Population Studies (E W Mengesha MPH), Bahir Dar University, Bahir Dar City, Ethiopia; School of Business (Prof M Ausloos PhD), University of Leicester, Leicester, UK; Center for Health Systems Research (L Avila-Burgos ScD, Prof E Serván-Mori DSc), National Institute of Public Health, Cuernavaca, Mexico; Department of Health Policy Planning and Management (M A Ayanore PhD), University of Health and Allied Sciences, Ho, Ghana; Department of Public Health Medicine (T K Babalola MSc), University of KwaZulu-Natal, Durban, South Africa; Department of Community Health and Primary Care (T K Babalola MSc), Department of Psychiatry (A T Olagunju MD), University of Lagos, Lagos, Nigeria; Department of Chemistry (Prof M Bagherzadeh PhD, N Rabiee MSc), Sharif University of Technology, Tehran, Iran; Unit of Biochemistry, Faculty of Medicine (A A Baig PhD) and School of Health Sciences (A A Baig PhD), Universiti Sultan Zainal Abidin, Kuala Terengganu, Malaysia; Department of Hypertension (Prof M Banach PhD), Medical University of Lodz, Lodz, Poland; Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland (Prof M Banach PhD); School of Health Sciences (Prof S K Banerjee PhD), Walden University, Minneapolis, MN, USA; Department of Ophthalmology, (Prof J B Jonas MD), Heidelberg Institute of Global Health (HIGH) (Prof T W Bärnighausen MD, S Kohler PhD), Heidelberg University, Heidelberg, Germany; Division of General Internal Medicine (Prof A Sheikh MD), T.H. Chan School of Public Health (Prof T W Bärnighausen MD), Harvard University, Boston, MA, USA (M G Shrimme MD); Department of Primary Care and Public Health (Prof S Rawaf MD, R Palladino MD), Imperial College Business School (D Kusuma DSc), School of Public Health (S Basu PhD), WHO Collaborating Centre for Public Health Education and Training (D L Rawaf MD), Imperial College London, London, UK; Department of Psychiatry (Prof B T Baune PhD), University of Münster, Münster, Germany; Department of Psychiatry (Prof B T Baune PhD), Melbourne Medical School, Melbourne, VIC, Australia; Epidemiology Department (M Dianatinasab MSc), Health Human Resources Research Center (M Bayati PhD), Non-Communicable Diseases Research Center (S G Sepanlou MD, Prof R Malekzadeh MD), Shiraz University of Medical Sciences, Shiraz, Iran; Department of Medicine (A E Berman MD), Augusta University, Augusta, GA, USA; Department of Forensic Medicine (J Padubidri MD), Department of Health Information Management (R Bhageerathy PhD), Kasturba Medical College (P Rathi MD), Manipal Academy of Higher Education, Manipal, India (R Bhageerathy PhD); Department of Community Medicine and Family Medicine (Prof P Bhardwaj MD), All India Institute of Medical Sciences, Jodhpur, India; Department of Community Medicine, Datta Meghe Institute of Medical Sciences (Prof P Bhardwaj MD), Wardha, India; Department of Computer Science and Information Technology (M Bohluli PhD), Institute for Advanced Studies in Basic Sciences, Zanjan, Iran; Research and Innovation Department (M Bohluli PhD), Petanux Research GmbH, Bonn, Germany; Department of Health Care Management (Prof R Busse PhD), Technical University of Berlin, Berlin, Germany; School of Public Health and Administration (L Cahuana-Hurtado PhD), Peruvian University Cayetano Heredia, Lima, Peru; Internal Medicine Department (Prof L L A Cámara MD), Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina; Comisión Directiva (Prof L L A Cámara MD), Argentine Society of Medicine, Ciudad Autónoma de Buenos Aires, Argentina (Prof P R Valdez Med); Colombian National Health Observatory (C A Castañeda-Orjuela MD), National Institute of Health, Bogota, Colombia; Epidemiology and Public Health Evaluation Group (C A Castañeda-Orjuela MD), National University of Colombia, Bogota, Colombia; National School of Public Health (F Catalá-López PhD), Institute of Health Carlos III, Madrid, Spain; Clinical Epidemiology Program (F Catalá-López PhD), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Infection and Global Health Research Division (M Cevik MD), University of St Andrews, St Andrews, UK; Regional Infectious Diseases Unit (M Cevik MD), NHS National Services Scotland, Edinburgh, UK; Department of Medicine (V Chattu MD), University of Toronto, Toronto, ON, Canada; Public Health Foundation of India, Gurugram, India (Prof L Dandona MD, Prof R Dandona PhD, G Kumar PhD, A Pandey PhD); Department of Epidemiology (M Dianatinasab MSc), Shahroud University of Medical Sciences, Shahroud, Iran; Center of Excellence in Public Health Nutrition (H T Do MD), Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam; Biotechnology Research Center (M Moghadaszadeh PhD), Department of Health Policy and Economy (L Doshmangir PhD), Department of Medical Surgical Nursing (M Ghafourifard PhD), Molecular Medicine Research Center (M Moghadaszadeh PhD), Social Determinants of Health Research Center (S Karimi PhD), Tabriz University of Medical Sciences, Tabriz, Iran; Pediatric Dentistry and Dental Public Health Department (Prof M El Tantawi PhD), Alexandria University, Alexandria, Egypt; Department of Healthcare Management (E Hasanpoor PhD), Maragheh University of Medical Sciences, Maragheh, Iran (F Esmaeilzadeh PhD); Computer Science Department (M Hosseinzadeh PhD), Department of Diplomacy and Public Relations (A Omar Bali PhD), Department of Information Technology (A Mohammad Darwesh PhD), Department of Political Science, College of Law and Politics (A Faraj PhD), University of Human Development, Sulaimaniyah, Iraq; Institute of Gerontological Health Services and Nursing Research (F Fischer PhD), Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany; Institute of Gerontology (N A Foigt PhD), National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; Department of Cardiovascular Medicine (M M Gad MD), Cleveland Clinic, Cleveland, OH, USA; Gillings School of Global Public Health (M M Gad MD), University of North Carolina Chapel Hill, Chapel Hill, NC, USA; Department of Computer Engineering (M Hosseinzadeh PhD), Department of Biology (A Gholamian MSc), Young Researchers and Elite Club (A Gholamian MSc), Islamic Azad University, Tehran, Iran; Department of Computer Science, Metropolitan College (R Rawassizadeh PhD), Department of Dermatology (A Grada MD), Health Informatic Lab, Metropolitan College (Z Javaheri PhD), Boston University, Boston, MA, USA; Institute for Global Health (H Haghparast Bidgoli PhD), University College London, London, UK; School of Health and Environmental Studies (Prof S Hamidi DrPH), Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates; Department of Vital and Health Statistics

(H L Harb MPH), Ministry of Public Health, Beirut, Lebanon; School of Public Health (D Hendrie PhD, T R Miller PhD), Curtin University, Perth, WA, Australia; Department of Pediatrics, Dell Medical School (M K Hole MD), University of Texas Austin, Austin, TX, USA; Clinical Legal Medicine Department (S Hostiu PhD), National Institute of Legal Medicine Mina Minovici, Bucharest, Romania; School of Public Health (T M Huda PhD), Sydney Medical School (S Islam PhD), University of Sydney, Sydney, NSW, Australia; Maternal and Child Health Division (T M Huda PhD, S Zaman MPH), International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh; Department of Public Health and Community Medicine (Prof A Humayun PhD), Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Shaikh Zayed Federal Postgraduate Medical Institute at Shaikh Zayed Medical Complex, Lahore, Pakistan; Department of Occupational Safety and Health (Prof B Hwang PhD), China Medical University, Taichung, Taiwan; Department of Community Medicine (O S Ilesanmi PhD), University College Hospital, Ibadan, Ibadan, Nigeria; Global Health and Development Department (Prof U Iqbal PhD), Taipei Medical University, Taipei City, Taiwan; Institute for Physical Activity and Nutrition (S Islam PhD), Deakin University, Burwood, VIC, Australia; School of Psychology and Public Health (M Islam PhD), La Trobe University, Melbourne, VIC, Australia; Social Determinants of Health Research Center, Health Research Institute (M A Jahani PhD), Babol University of Medical Sciences, Babol, Iran; N.A. Semashko Department of Public Health and Healthcare (Prof M Jakovljevic PhD), I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Global Health, Economics and Policy (Prof M Jakovljevic PhD), University of Kragujevac, Kragujevac, Serbia; Beijing Institute of Ophthalmology, Beijing Ophthalmology and Visual Sciences Key Laboratory (Prof J B Jonas MD), Beijing Tongren Hospital, Beijing, China; Gastrointestinal and Liver Disease Research Center (F Joukar PhD, Prof F Mansour-Ghanaei PhD), Guilan University of Medical Sciences, Rasht, Iran; Department of Family Medicine and Public Health (J J Józwiak PhD), University of Opole, Opole, Poland; Institute of Family Medicine and Public Health (M Jürisson PhD), University of Tartu, Tartu, Estonia; Health Services Management Department (R Kalhor PhD), Social Determinants of Health Research Center, Research Institute for Prevention of Non-Communicable Diseases (R Kalhor PhD), Qazvin University of Medical Sciences, Qazvin, Iran; International Research Center of Excellence (G A Kayode PhD), Institute of Human Virology Nigeria, Abuja, Nigeria; Julius Centre for Health Sciences and Primary Care (G A Kayode PhD), Utrecht University, Utrecht, Netherlands; Faculty of Health (Y Kinfu PhD), University of Canberra, Canberra, ACT, Australia; Murdoch Children's Research Institute (Y Kinfu PhD), Royal Children's Hospital, Melbourne, VIC, Australia; School of Health Sciences (Prof A Kisa PhD), Kristiania University College, Oslo, Norway; Department of Midwifery and Reproductive Health (S Masoumi PhD), Neurophysiology Research Center (H Komaki MD), Hamadan University of Medical Sciences, Hamadan, Iran; Brain Engineering Research Center (H Komaki MD), Institute for Research in Fundamental Sciences, Tehran, Iran; Independent Consultant, Jakarta, Indonesia (S Kosen MD); Independent Consultant, Karachi, Pakistan (M A Shaikh MD); Global Health Department (A Kotlo MS), Vancouver Virology Centre, Vancouver, BC, Canada; Biomedical Research Networking Center for Mental Health Network (CIBERSAM) (A Koyanagi MD), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain (A Koyanagi MD); Faculty of Public Health (D Kusuma DSc), University of Indonesia, Depok, Indonesia; HelpMeSee, New York, NY, USA (Prof V C Lansingh PhD); International Relations Department (Prof V C Lansingh PhD), Mexican Institute of Ophthalmology, Queretaro, Mexico; Department of Medical Sciences (Prof A O Larsson PhD), Uppsala University, Uppsala, Sweden; Department of Clinical Chemistry and Pharmacology (Prof A O Larsson PhD), Uppsala University Hospital, Uppsala, Sweden; Department of Otorhinolaryngology (S Lasrado MS), Father Muller Medical College, Mangalore, India; Department of Medicine, School of Clinical Sciences at Monash Health (S Zaman MPH), School of Pharmacy (S W H Lee PhD), Monash University, Bandar Sunway, Malaysia; School of Pharmacy (S W H Lee PhD), Taylor's University Lakeside Campus, Subang Jaya, Malaysia; Department of Medicine (L Lim MRCP), University of Malaya, Kuala Lumpur, Malaysia; Department of Medicine and Therapeutics (L Lim MRCP), The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China; Radiology Department (H Magdy Abd El Razeq MD), Mansoura Faculty of Medicine, Mansoura, Egypt; Social Determinants of Health Research Center (M M Mahdavi PhD), Saveh University of Medical Sciences, Saveh, Iran; Academy of Medical Science, Saveh, Iran (M M Mahdavi PhD); School of Medicine and Surgery (Prof L G Mantovani DSc), University of Milan Bicocca, Monza, Italy; Value-Based Healthcare Unit (Prof L G Mantovani DSc), IRCCS MultiMedica, Sesto San Giovanni, Italy; Department of Economics (Prof G Martinez PhD), Autonomous Technology Institute of Mexico, Mexico City, Mexico; Forensic Medicine Division (Prof R G Menezes MD), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; Breast Surgery Unit (T J Meretoja MD), Neurocenter (A Meretoja MD), Helsinki University Hospital, Helsinki, Finland; University of Helsinki, Helsinki, Finland (T J Meretoja MD); School of Health Sciences (A Meretoja MD), University of Melbourne, Parkville, VIC, Australia; Clinical Microbiology and Parasitology Unit (T Mestrovic PhD), Dr. Zora Profzic Polyclinic, Zagreb, Croatia; University Centre Varazdin (T Mestrovic PhD), University North, Varazdin, Croatia; Institute for Social Innovation, Skopje, Macedonia (N Milevska Kostova PhD); Health Policy and Management (N Milevska Kostova PhD), Centre for Regional Policy Research and Cooperation 'Studiorum', Skopje, Macedonia; Pacific Institute for Research and Evaluation, Calverton, MD, USA (T R Miller PhD); President's Office (A Mirica PhD), National Institute of Statistics, Bucharest, Romania; Faculty of Internal Medicine (Prof E M Mirrakhimov MD), Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan; Department of Atherosclerosis and Coronary Heart Disease (Prof E M Mirrakhimov MD), National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan; Department of Epidemiology and Biostatistics (A Mohammadian-Hafshejani PhD), Shahrekord University of Medical Sciences, Shahrekord, Iran; Kashmar Center of Higher Health Education (R Mohammadpourhodki MSc), Mashhad University of Medical Sciences, Mashhad, Iran; Health Systems and Policy Research Unit (S Mohammed PhD), Ahmadu Bello University, Zaria, Nigeria; School of Economics (M K Muriithi PhD), University of Nairobi, Nairobi, Kenya; Department of Microbiology and Immunology (S Muthupandian PhD), Mekelle University, Mekelle, Ethiopia; Department of Health Services Research (C Myint PhD), Maastricht University, Maastricht, New Zealand; Research and Analytics Department (A J Nagarajan MTech), Initiative for Financing Health and Human Development, Chennai, India; Research and Analytics Department (A J Nagarajan MTech), Bioinsilico Technologies, Chennai, India; Institute for Global Health Innovations (C T Nguyen MPH, H L T Nguyen MPH), Duy Tan University, Hanoi, Vietnam; School of Public Health (J Nonvignon PhD), University of Ghana, Accra, Ghana; Centre for Heart Rhythm Disorders (J Noubiap MD), University of Adelaide, Adelaide, WC, Australia; Department of Preventive Medicine (I Oh PhD), Kyung Hee University, Dongdaemun-gu, South Korea; Department of Psychiatry and Behavioural Neurosciences (A T Olagunju MD), McMaster University, Hamilton, ON, Canada; Centre for Healthy Start Initiative, Lagos, Nigeria (J O Olusanya MBA, B O Olusanya PhD); Department of Pharmacology and Therapeutics (Prof O E Onwujekwe PhD), University of Nigeria Nsukka, Enugu, Nigeria; Laboratory of Public Health Indicators Analysis and Health Digitalization (S S Oststavnov PhD, N Oststavnov BA), Moscow Institute of Physics and Technology, Dolgoprudny, Russia; Department of Health Care Administration and Economics (Prof V Vlassov MD), Department of Project Management (S S Oststavnov PhD), National Research University Higher School of Economics, Moscow, Russia; Academic Department (N Oststavnov BA), Unium Ltd., Moscow, Russia; Department of Public Health (R Palladino MD), University of Naples Federico II, Naples, Italy; Faculty of Economics and Business (Prof M J Postma PhD), Department of General Practice (J F M van Boven PhD), University Medical Center Groningen (Prof M J Postma PhD, J F M van Boven PhD), University of Groningen, Groningen, Netherlands; Centro De Investigaciones Clínicas (S I Prada PhD), Fundación Valle del Lili, Cali, Colombia; Centro de Estudios en Protección Social y Economía de la Salud (S I Prada PhD),



ICESI University, Cali, Colombia; Health Sciences Department (D R A Pribadi MSc), Muhammadiyah University of Surakarta, Sukoharjo, Indonesia; Biomedical Engineering Department (Prof M Rabiee PhD), Amirkabir University of Technology, Tehran, Iran; Thalassemia and Hemoglobinopathy Research Center (F Rahim PhD), Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Policy Research Institute, Kathmandu, Nepal (C L Ranabhat PhD); Institute for Poverty Alleviation and International Development (C L Ranabhat PhD), Yonsei University, Wonju, South Korea; Department of Oral Pathology (S Rao MDS), Srinivas Institute of Dental Sciences, Mangalore, India; Academic Public Health Department (Prof S Rawaf MD), Public Health England, London, UK; University College London Hospitals, London, UK (D L Rawaf MD); School of Health, Medical and Applied Sciences (L Rawal PhD), CQ University, Sydney, NSW, Australia; Research Institute for Endocrine Sciences (S S N Irvani MD), Department of Epidemiology (S Sabour PhD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Global Health and Development (O M Salman MSc), London School of Hygiene and Tropical Medicine, London, UK; Global Health Institute (O M Salman MSc), American University of Beirut, Beirut, Lebanon; Center for Health Policy and Center for Primary Care and Outcomes Research (Prof J A Salomon PhD), Stanford University, Stanford, CA, USA; Department of Entomology (A M Samy PhD), Ain Shams University, Cairo, Egypt; Department of Surgery (Prof J Sanabria MD), Marshall University, Huntington, WV, USA; Department of Nutrition and Preventive Medicine (Prof J Sanabria MD), Case Western Reserve University, Cleveland, OH, USA; Department of Community Medicine (J V Santos MD), University of Porto, Porto, Portugal; Department of Public Health (J V Santos MD), Regional Health Administration Do Norte I.P., Vila Nova de Gaia, Portugal; Centre-School of Public Health and Health Management (Prof M M Santric Milicevic PhD), Institute of Social Medicine (Prof M M Santric Milicevic PhD), University of Belgrade, Belgrade, Serbia; Department of Infectious Diseases and Tropical Medicine (B P Sao Jose PhD), Federal University of Minas Gerais, Belo Horizonte, Brazil; GSK Biologicals, Wavre, Belgium (M Savic PhD); Oral Diagnosis, Digital Health and Health Services Research (Prof F Schwendicke PhD), Charité University Medical Center Berlin, Berlin, Germany; Emergency Department (S Senthilkumaran MD), Manian Medical Centre, Erode, India; Country Programmes (H Setayesh MD), Gavi, the Vaccine Alliance, Le Grand-Saconnex, Switzerland; Centre for Medical Informatics (Prof A Sheikh MD), University of Edinburgh, Edinburgh, UK; Institute for Population Health (Prof K Shibuya MD), School of Population Health and Environmental Sciences (Prof C D A Wolfe MD), King's College London, London, UK; Department of Law, Economics, Management and Quantitative Methods (Prof B Simonetti PhD), University of Sannio, Benevento, Italy; WSB University in Gdańsk, Gdańsk, Poland (Prof B Simonetti PhD); Department of Medicine (Prof J A Singh MD), University of Alabama at Birmingham, Birmingham, AL, USA; Medicine Service (Prof J A Singh MD), US Department of Veterans Affairs (VA), Birmingham, AL, USA; Department of Humanities and Social Sciences (P Singh MSc), Indian Institute of Technology, Roorkee, Roorkee, India; Department No 16 (V Y Skryabin MD), Moscow Research and Practical Centre on Addictions, Moscow, Russia; Department of Emergency Nursing (A Soheili PhD), Nursing Care Research Center (A Soheili PhD), Semnan University of Medical Sciences, Semnan, Iran; Department of Medicine (Prof R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain; Carlos III Health Institute (Prof R Tabarés-Seisdedos PhD), Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Madrid, Spain; Institute of Public Health, Faculty of Health Sciences (R Topor-Madry PhD), Jagiellonian University Medical College, Kraków, Poland; Agency for Health Technology Assessment and Tariff System, Warszawa, Poland (R Topor-Madry PhD); Department of Pathology and Legal Medicine (M R Tovani-Palone MSc), University of São Paulo, Ribeirão Preto, Brazil; Department of Health Economics (B X Tran PhD), Hanoi Medical University, Hanoi, Vietnam; School of Government (E A Undurraga PhD), Pontifical Catholic University of Chile, Santiago, Chile; Schneider Institutes for Health Policy (E A Undurraga PhD), Brandeis University, Waltham, MA, USA; Velez Sarsfield Hospital, Buenos Aires, Argentina (Prof P R Valdez Med); UKK Institute,

Tampere, Finland (Prof T J Vasankari MD); Department of Medical and Surgical Sciences (Prof F S Violante MD), University of Bologna, Bologna, Italy; Occupational Health Unit (Prof F S Violante MD), Sant'Orsola Malpighi Hospital, Bologna, Italy; NIHR Biomedical Research Centre (Prof C D A Wolfe MD), Guy's and St. Thomas' NHS Foundation Trust & Kings College London, London, UK; School of International Development and Global Studies (Prof S Yaya PhD), University of Ottawa, Ottawa, ON, Canada; Department of Health Management, Policy and Economics (V Yazdi-Feyzabadi PhD), Health Services Management Research Center (V Yazdi-Feyzabadi PhD), Kerman University of Medical Sciences, Kerman, Iran; Centre for Suicide Research and Prevention (Prof P Yip PhD), Department of Social Work and Social Administration (Prof P Yip PhD), University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Neuropsychopharmacology (N Yonemoto MPH), National Center of Neurology and Psychiatry, Kodaira, Japan; Department of Health Policy and Management (Prof M Z Younis PhD), Jackson State University, Jackson, MS, USA; School of Medicine (Prof M Z Younis PhD), Tsinghua University, Beijing, China; Department of Epidemiology and Biostatistics, School of Health Sciences (Prof C Yu PhD), Department of Preventive Medicine (Z Zhang PhD), Global Health Institute (Prof C Yu PhD), Wuhan University, Wuhan, China; Department of Epidemiology (Prof Z Zaidi PhD), University Hospital of Setif, Setif, Algeria; Laboratory of Genetics and Genomics (Prof M S Zastrozhin PhD), Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia; Department of Addictology (Prof M S Zastrozhin PhD), Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia; and Nuffield Department of Medicine (Y Zhao MPH), University of Oxford, Oxford, UK.

#### Contributors

J L Dieleman, A E Micah, Y Su, M T Schneider, and M Sahu prepared the first draft. J L Dieleman and C J L Murray provided overall guidance. A Chapin, J L Dieleman, A E Micah, Y Su, and G Tsakalos managed the overall project. J L Dieleman, A E Micah, Y Su, G Tsakalos, S D Bachmeier, A Chapin, I E Cogswell, S W Crosby, B Cunningham, A C Harle, E R Maddison, M Moitra, M Sahu, M T Schneider, K E Simpson, H N Stutzman, R R Zende, and B S Zlavoag analysed data. J L Dieleman, A E Micah, and M T Schneider finalised the manuscript on the basis of comments from other authors and reviewer feedback. All other authors provided data or reviewed and contributed to the report, or both.

#### Declaration of interests

C A T Antonio reports personal fees from Johnson & Johnson (Philippines) outside of the submitted work. A E Berman reports personal fees from Biosense Webster outside of the submitted work. S L James reports grants from Sanofi Pasteur and future employment with Genentech/Roche outside of the submitted work. J J Jóźwiak reports personal fees from VALEANT, ALAB Laboratoria, and AMGEN outside of the submitted work. M J Postma reports grants and personal fees from MSD, GlaxoSmithKline (GSK), Pfizer, Boehringer Ingelheim, Novavax, Bristol-Myers Squibb, AstraZeneca, Sanofi, Seqirus, and IQVIA; grants from Bayer, BioMerieux, WHO, the European Union? FIND, Antilope, DIKTI, LPDP, and BUDI; personal fees from Novartis, Pharmerit, and Quintiles; holds stocks in Ingress Health and Pharmacoeconomics Advice Groningen; and is advisor to Asc Academics outside of the submitted work. M Savic reports employment with the GSK group of companies and hold restricted shares in the GSK group of companies. M G Shrimme reports grants from Mercy Ships and Damon Runyon Cancer Research Foundation outside of the submitted work. J A Singh reports personal fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology, and Simply Speaking; participating in the Speaker's Bureau at Simply Speaking; owning stock options in Amarin Pharmaceuticals and Viking Pharmaceuticals; membership in the FDA Arthritis Advisory Committee, Veterans Affairs Rheumatology Field Advisory Committee, and in the Steering Committee of Outcome Measures in Rheumatology (OMERACT), and acting as Editor and the

Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis outside of the submitted work. All other authors declare no competing interests.

#### Data sharing

Data used for this study were extracted from publicly available sources that are listed in the appendix. Further details are available on the Global Health Data Exchange website.

#### Acknowledgments

R O Akinyemi acknowledges supports from the US National Institutes of Health (NIH; Grant U01HG010273) as part of the H3Africa Consortium and a Global Challenges Research Fund (GCRF) fellowship grant (FLR/R1/191813) from the UK Royal Society and the African Academy of Sciences. S M Aljunid acknowledges International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia and Department of Health Policy and Management, and Faculty of Public Health, Kuwait University for the approval and support to participate in this research project. M Ausloos acknowledges partial support from a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (project number PN-III-P4-ID-PCCF-2016-0084). T W Bärnighausen acknowledges support from the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the Federal Ministry of Education and Research. S I Hay acknowledges primary support from the Bill & Melinda Gates Foundation (grant OPP1132415). Claudiu Herteliu acknowledges partial support from a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (project number PN-III-P4-ID-PCCF-2016-0084) and from a grant co-funded by European Fund for Regional Development through Operational Program for Competitiveness (project ID P\_40\_382). B-F Hwang acknowledges support from China Medical University (CMU 107-Z-04), Taichung, Taiwan. S M S Islam acknowledges funding from the National Heart Foundation of Australia and Deakin University. M Jakovljevic acknowledges the Ministry of Education Science and Technological Development of the Republic of Serbia for co-funding for the Serbian part of this Global Burden of Disease (GBD) contribution (grant OI 175 014). A M Samy acknowledges support from a fellowship from the Egyptian Fulbright Mission Program. M M Santric Milicevic acknowledges support from The Ministry of Education, Science and Technological Development, Serbia (contract number 175087). A Sheikh acknowledges support from Health Data Research UK. R Tabarés-Seisdedos acknowledges support in part from Generalitat Valenciana (grant number PROMETEOII/2015/021) and from Instituto de Salud Carlos III-La Federación Española de Enfermedades Raras (national grant PI17/00719). J F M van Boven acknowledges support from the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, University of Groningen, Groningen Netherlands. S B Zaman acknowledges the Australian Government research training programme for providing a scholarship in support of his academic career.

Editorial note: the *Lancet* Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

#### References

- GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 2091–138.
- GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. *Lancet* 2017; **390**: 1423–59.
- WHO. Thirteenth general programme of work 2019–2023. 2019. Geneva: World Health Organization, Oct 25, 2019. <https://www.who.int/about/what-we-do/thirteenth-general-programme-of-work-2019-2023> (accessed Feb 17, 2020).
- United Nations Secretary-General's roadmap for financing the 2030 agenda for sustainable development 2019 - 2021. New York, NY: United Nations, July, 2019. <https://www.un.org/sustainabledevelopment/wp-content/uploads/2019/07/UN-SG-Roadmap-Financing-the-SDGs-July-2019.pdf> (accessed Feb 17, 2020).
- United Nations Statistics Division. SDG Indicators Metadata repository. New York, NY: United Nations. <https://unstats.un.org/sdgs/metadata/?Text=&Goal=3&Target=3.8> (accessed Feb 17, 2020).
- Somkotra T, Lagrada LP. Payments for health care and its effect on catastrophe and impoverishment: experience from the transition to Universal Coverage in Thailand. *Soc Sci Med* 2008; **67**: 2027–35.
- Chang AY, Cowling K, Micah AE, et al. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. *Lancet* 2019; **393**: 2233–60.
- Haakenstad A, Moses MW, Tao T, et al. Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study. *Lancet HIV* 2019; **6**: e382–95.
- Haakenstad A, Harle AC, Tsakalos G, et al. Tracking spending on malaria by source in 106 countries, 2000–16: an economic modelling study. *Lancet Infect Dis* 2019; **19**: 703–16.
- WHO. Global health expenditure database. Geneva: World Health Organization, March 17, 2020. <http://www.who.int/health-accounts/gheed/en/> (accessed Jan 29, 2020).
- World Economic Outlook, October 2019: Global manufacturing downturn, rising trade barriers. Washington, DC: International Monetary Fund. <https://www.imf.org/en/Publications/WEO/Issues/2019/10/01/world-economic-outlook-october-2019> (accessed Feb 17, 2020).
- Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017; **390**: 1345–422.
- UNAIDS. NASA country reports. Geneva: Joint United Nations Programme on HIV/AIDS. <https://www.unaids.org/en/dataanalysis/knowyourresponse/nasacountryreports> (accessed Feb 17, 2020).
- Moses MW, Pedroza P, Baral R, et al. Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016. *Lancet Public Health* 2019; **4**: e49–73.
- Institute for Health Metrics and Evaluations. Financing global health 2018: countries and programs in transition. Seattle, WA: Institute for Health Metrics and Evaluations, 2019. <http://www.healthdata.org/policy-report/financing-global-health-2018-countries-and-programs-transition> (accessed Feb 17, 2020).
- Wagstaff A, van Doorslaer E. Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993–1998. *Health Econ* 2003; **12**: 921–34.
- Xu K, Evans DB, Kawabata K, Zeramini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. *Lancet* 2003; **362**: 111–17.
- James SL, Gubbins P, Murray CJ, Gakidou E. Developing a comprehensive time series of GDP per capita for 210 countries from 1950 to 2015. *Popul Health Metr* 2012; **10**: 12.
- Global Burden of Disease Health Financing Collaborator Network. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. *Lancet* 2018; **391**: 1783–98.
- Mills TC. Time series techniques for economists. Cambridge: Cambridge University Press, 1991.
- Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr* 2012; **10**: 1.
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1859–922.
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1789–858.

- 24 GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1995–2051.
- 25 Health Equity and Financial Protection Indicators. Washington, DC: The World Bank. December 2018. <https://datacatalog.worldbank.org/dataset/hefpi> (accessed Feb 17, 2020).
- 26 Cylus J, Thomson S, Evetovits T. Catastrophic health spending in Europe: equity and policy implications of different calculation methods. *Bull World Health Organ* 2018; **96**: 599–609.
- 27 United Nations Population Fund. This is how much it will cost to realize the world we want. New York, NY: United Nations Population Fund, Nov 13, 2019. <https://www.unfpa.org/news/how-much-it-will-cost-realize-world-we-want> (accessed Feb 17, 2020).
- 28 Stenberg K, Hanssen O, Edejer TT-T, et al. Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries. *Lancet Glob Health* 2017; **5**: e875–87.
- 29 UNAIDS. Fast-track update on investments needed in the AIDS response. Geneva: Joint United Nations Programme on HIV/AIDS, April 1, 2016. [https://www.unaids.org/en/resources/documents/2016/unaids\\_fast-track\\_update\\_investments\\_needed](https://www.unaids.org/en/resources/documents/2016/unaids_fast-track_update_investments_needed) (accessed Feb 17, 2020).
- 30 WHO. Global tuberculosis report 2019. Geneva: World Health Organization, 2019 [https://www.who.int/tb/publications/global\\_report/en/](https://www.who.int/tb/publications/global_report/en/) (accessed Feb 17, 2020).
- 31 WHO. World Malaria Report 2019. Geneva: World Health Organization: 2019. <https://www.who.int/publications-detail/world-malaria-report-2019> (accessed March 31, 2020).
- 32 WHO. WHO urges countries to invest in eliminating hepatitis. Geneva: World Health Organization, July 26, 2019. <https://www.who.int/news-room/detail/26-07-2019-who-urges-countries-to-invest-in-eliminating-hepatitis> (accessed Feb 17, 2020).
- 33 WHO. Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected tropical diseases. Geneva: World Health Organization, 2015. [https://www.who.int/neglected\\_diseases/9789241564861/en/](https://www.who.int/neglected_diseases/9789241564861/en/) (accessed Feb 17, 2020).
- 34 Okiror S. Cost of ending maternal deaths laid bare as \$115bn funding shortfall revealed. London: The Guardian, Nov 13, 2019. <https://www.theguardian.com/global-development/2019/nov/13/cost-of-ending-maternal-deaths-laid-bare-as-115bn-funding-shortfall-revealed-nairobi-summit> (accessed Jan 29, 2020).
- 35 Jamison DT, Alwan A, Mock CN, et al. Universal health coverage and intersectoral action for health: key messages from *Disease Control Priorities*, 3rd edition. *Lancet* 2018; **391**: 1108–20.
- 36 Watkins DA, Qi J, Horton S. Costing universal health coverage: the DCP3 model. University of Washington, Nov 13, 2017. <http://dcp-3.org/resources/costs-and-affordability-essential-universal-health-coverage-low-and-middle-income> (accessed Feb 18, 2020).
- 37 Move Humanity. Closing the SDG budget gap. Sustainable Development Solutions Network Costing and Financing team, Move Humanity, Sept 24, 2018. <https://movehumanity.org/article/closing-the-sdg-budget-gap/> (accessed Dec 13, 2019).
- 38 GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1736–88.
- 39 Sustainable Development Solutions Network. SDG costing & financing for low-income developing countries. Paris, New York, NY: Sustainable Development Solutions Network, Sept 23, 2019. <http://resources.unsd.org/sdg-costing-financing-for-low-income-developing-countries> (accessed Feb 18, 2020).
- 40 Gasper V, Amaglobeli D, Garcia-Escribano M, Prady D, Soto M. Fiscal policy and development: human, social, and physical investments for the SDGs. Washington, DC: International Monetary Fund, Jan 23, 2019. <https://www.imf.org/en/Publications/Staff-Discussion-Notes/Issues/2019/01/18/Fiscal-Policy-and-Development-Human-Social-and-Physical-Investments-for-the-SDGs-46444> (accessed Feb 18, 2020).
- 41 Sterck O, Roser M, Ncube M, Thewissen S. Allocation of development assistance for health: is the predominance of national income justified? *Health Policy Plan* 2018; **33** (suppl 1): i14–23.
- 42 Brooks BPC, Dieleman JL, Haakenstad A, Hanlon M. Allocating development assistance for health. *Lancet Glob Health* 2014; **2**: S29.
- 43 Chi Y-L, Bump JB. Resource allocation processes at multilateral organizations working in global health. *Health Policy Plan* 2018; **33** (suppl 1): i4–13.
- 44 Berman P, Ahuja R, Bhandari L. The impoverishing effect of healthcare payments in India: new methodology and findings. *Econ Polit Wkly* 2010; **45**: 65–71.
- 45 Aregbeshola BS, Khan SM. Out-of-pocket payments, catastrophic health expenditure and poverty among households in Nigeria 2010. *Int J Health Policy Manag* 2018; **7**: 798–806.
- 46 Dieleman JL, Cowling K, Agyepong IA, et al. The G20 and development assistance for health: historical trends and crucial questions to inform a new era. *Lancet* 2019; **394**: 173–83.
- 47 Moon S, Røttingen J-A, Frenk J. Global public goods for health: weaknesses and opportunities in the global health system. *Health Econ Policy Law* 2017; **12**: 195–205.
- 48 Bump JB, Reddiar SK, Soucat A. When do governments support common goods for health? Four cases on surveillance, traffic congestion, road safety, and air pollution. *Health Syst Reform* 2019; **5**: 293–306.
- 49 Soucat A. Financing common goods for health: fundamental for health, the foundation for UHC. *Health Syst Reform* 2019; **5**: 263–67.
- 50 Implementation of the International Health Regulations (2005): report of the Review Committee on Second Extensions for Establishing National Public Health Capacities and on IHR Implementation: report by the Director-General. Geneva: World Health Organization, 2015. <https://apps.who.int/iris/handle/10665/251717> (accessed Feb 18, 2020).
- 51 Yamey G, Jamison D, Hanssen O, Soucat A. Financing global common goods for health: when the world is a country. *Health Syst Reform* 2019; **5**: 334–49.
- 52 Schäfferhoff M, Chodavadia P, Martinez S, et al. International funding for global common goods for health: an analysis using the Creditor Reporting System and G-FINDER databases. *Health Syst Reform* 2019; **5**: 350–65.
- 53 Second Annual UHC Financing forum: greater efficiency for better health and financial protection; Washington, DC, USA: April 20–21, 2017. <http://online.fihphtml5.com/qmoq/gzif/#p=1> (accessed Dec 13, 2019).